US20210348206A1 - Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom - Google Patents
Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom Download PDFInfo
- Publication number
- US20210348206A1 US20210348206A1 US17/360,695 US202117360695A US2021348206A1 US 20210348206 A1 US20210348206 A1 US 20210348206A1 US 202117360695 A US202117360695 A US 202117360695A US 2021348206 A1 US2021348206 A1 US 2021348206A1
- Authority
- US
- United States
- Prior art keywords
- conditions
- infection
- budding yeast
- spp
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 50
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 22
- 230000001028 anti-proliverative effect Effects 0.000 title abstract description 16
- 239000000203 mixture Substances 0.000 title description 2
- 208000015181 infectious disease Diseases 0.000 claims abstract description 94
- 210000004027 cell Anatomy 0.000 claims description 159
- 230000012010 growth Effects 0.000 claims description 104
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 230000003278 mimic effect Effects 0.000 claims description 45
- 238000000338 in vitro Methods 0.000 claims description 42
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 38
- 210000005253 yeast cell Anatomy 0.000 claims description 36
- 241000235343 Saccharomycetales Species 0.000 claims description 35
- 230000014509 gene expression Effects 0.000 claims description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 21
- 239000008121 dextrose Substances 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 18
- 239000001301 oxygen Substances 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 230000001360 synchronised effect Effects 0.000 claims description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 13
- 239000002953 phosphate buffered saline Substances 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 239000004202 carbamide Substances 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 9
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 8
- 241000235395 Mucor Species 0.000 claims description 8
- 210000002540 macrophage Anatomy 0.000 claims description 8
- 210000000440 neutrophil Anatomy 0.000 claims description 7
- 206010021143 Hypoxia Diseases 0.000 claims description 6
- 230000001146 hypoxic effect Effects 0.000 claims description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 102000016359 Fibronectins Human genes 0.000 claims description 5
- 108010067306 Fibronectins Proteins 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 102000016942 Elastin Human genes 0.000 claims description 4
- 108010014258 Elastin Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 229920002549 elastin Polymers 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims 3
- 108010063738 Interleukins Proteins 0.000 claims 3
- 206010048038 Wound infection Diseases 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 81
- 201000011510 cancer Diseases 0.000 abstract description 73
- 230000000813 microbial effect Effects 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 description 41
- 230000002538 fungal effect Effects 0.000 description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- 235000015097 nutrients Nutrition 0.000 description 28
- 230000001580 bacterial effect Effects 0.000 description 27
- 230000032823 cell division Effects 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 19
- 238000012216 screening Methods 0.000 description 19
- 230000035882 stress Effects 0.000 description 19
- 230000037361 pathway Effects 0.000 description 17
- 230000022131 cell cycle Effects 0.000 description 16
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 15
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 230000002503 metabolic effect Effects 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 241000221204 Cryptococcus neoformans Species 0.000 description 13
- 241000233866 Fungi Species 0.000 description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- JARYYMUOCXVXNK-UHFFFAOYSA-N Validamycin A Natural products OC1C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)CC1NC1C=C(CO)C(O)C(O)C1O JARYYMUOCXVXNK-UHFFFAOYSA-N 0.000 description 11
- JARYYMUOCXVXNK-CSLFJTBJSA-N validamycin A Chemical compound N([C@H]1C[C@@H]([C@H]([C@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)CO)[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O JARYYMUOCXVXNK-CSLFJTBJSA-N 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000010355 oscillation Effects 0.000 description 9
- 201000007336 Cryptococcosis Diseases 0.000 description 8
- 206010017533 Fungal infection Diseases 0.000 description 7
- 208000031888 Mycoses Diseases 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000003596 drug target Substances 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 241000222122 Candida albicans Species 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000000737 periodic effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 5
- 241000306281 Mucor ambiguus Species 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000007320 rich medium Substances 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 241001225321 Aspergillus fumigatus Species 0.000 description 4
- 241000222178 Candida tropicalis Species 0.000 description 4
- 244000241257 Cucumis melo Species 0.000 description 4
- 101000795074 Homo sapiens Tryptase alpha/beta-1 Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241000131448 Mycosphaerella Species 0.000 description 4
- 241000519856 Phyllosticta Species 0.000 description 4
- 241000813090 Rhizoctonia solani Species 0.000 description 4
- 102100029639 Tryptase alpha/beta-1 Human genes 0.000 description 4
- 229940091771 aspergillus fumigatus Drugs 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 230000006342 environmental stress response Effects 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 244000053095 fungal pathogen Species 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000029054 response to nutrient Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- -1 2% w/v/dextrose) Chemical class 0.000 description 3
- 244000291564 Allium cepa Species 0.000 description 3
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241000222199 Colletotrichum Species 0.000 description 3
- 241000186216 Corynebacterium Species 0.000 description 3
- 235000009854 Cucurbita moschata Nutrition 0.000 description 3
- 240000001980 Cucurbita pepo Species 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 102100021710 Endonuclease III-like protein 1 Human genes 0.000 description 3
- 101000970385 Homo sapiens Endonuclease III-like protein 1 Proteins 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241001361634 Rhizoctonia Species 0.000 description 3
- 101100365575 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SFG1 gene Proteins 0.000 description 3
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000008723 osmotic stress Effects 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000005000 reproductive tract Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 241000223600 Alternaria Species 0.000 description 2
- 101100433746 Arabidopsis thaliana ABCG29 gene Proteins 0.000 description 2
- 101100433755 Arabidopsis thaliana ABCG31 gene Proteins 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- 244000221633 Brassica rapa subsp chinensis Species 0.000 description 2
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 2
- 240000006740 Cichorium endivia Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 241001133184 Colletotrichum agaves Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000218631 Coniferophyta Species 0.000 description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 description 2
- 235000009852 Cucurbita pepo Nutrition 0.000 description 2
- 241000371644 Curvularia ravenelii Species 0.000 description 2
- 241001508802 Diaporthe Species 0.000 description 2
- 241000588698 Erwinia Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 241000223195 Fusarium graminearum Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 241000228456 Leptosphaeria Species 0.000 description 2
- 241000218922 Magnoliophyta Species 0.000 description 2
- 206010027236 Meningitis fungal Diseases 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 241000896238 Oidium Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 101100054289 Oryza sativa subsp. japonica ABCG34 gene Proteins 0.000 description 2
- 101100054294 Oryza sativa subsp. japonica ABCG36 gene Proteins 0.000 description 2
- 101100107601 Oryza sativa subsp. japonica ABCG45 gene Proteins 0.000 description 2
- 101100107604 Oryza sativa subsp. japonica ABCG48 gene Proteins 0.000 description 2
- 101150088582 PDR1 gene Proteins 0.000 description 2
- 101150078988 PDR3 gene Proteins 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 101000662819 Physarum polycephalum Terpene synthase 1 Proteins 0.000 description 2
- 101000830822 Physarum polycephalum Terpene synthase 2 Proteins 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 241001136503 Pleospora Species 0.000 description 2
- 241001148183 Pseudomonas savastanoi Species 0.000 description 2
- 241000287531 Psittacidae Species 0.000 description 2
- 241000173767 Ramularia Species 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000514831 Stemphylium botryosum Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 101150014929 TPS2 gene Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 101100400877 Trichophyton rubrum (strain ATCC MYA-4607 / CBS 118892) MDR1 gene Proteins 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 244000000005 bacterial plant pathogen Species 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 235000003733 chicria Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 201000010056 fungal meningitis Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000020354 squash Nutrition 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 244000283763 Acetobacter aceti Species 0.000 description 1
- 235000007847 Acetobacter aceti Nutrition 0.000 description 1
- 241000589212 Acetobacter pasteurianus Species 0.000 description 1
- 241001600124 Acidovorax avenae Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 1
- 241001135511 Agrobacterium rubi Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000010167 Allium cepa var aggregatum Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000223602 Alternaria alternata Species 0.000 description 1
- 241000212252 Alternaria dianthi Species 0.000 description 1
- 241000266416 Alternaria japonica Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 101100532518 Arabidopsis thaliana SAHH1 gene Proteins 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000726096 Aratinga Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 101100482039 Aspergillus niger tpsA gene Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 241000190150 Bipolaris sorokiniana Species 0.000 description 1
- 241000228439 Bipolaris zeicola Species 0.000 description 1
- 241001480061 Blumeria graminis Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001148605 Borreliella garinii Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000493583 Botryotinia narcissicola Species 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 241000123650 Botrytis cinerea Species 0.000 description 1
- 241001065413 Botrytis fabae Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000011297 Brassica napobrassica Nutrition 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 241000219192 Brassica napus subsp. rapifera Species 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- 244000304217 Brassica oleracea var. gongylodes Species 0.000 description 1
- 240000004073 Brassica oleracea var. viridis Species 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241001509299 Brucella canis Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000009025 Carya illinoensis Nutrition 0.000 description 1
- 244000068645 Carya illinoensis Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 235000003301 Ceiba pentandra Nutrition 0.000 description 1
- 244000146553 Ceiba pentandra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001157813 Cercospora Species 0.000 description 1
- 241000905906 Cercospora apii Species 0.000 description 1
- 241000530549 Cercospora beticola Species 0.000 description 1
- 241001658057 Cercospora kikuchii Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241001635604 Cladosporium arthropodii Species 0.000 description 1
- 241001149955 Cladosporium cladosporioides Species 0.000 description 1
- 241000186650 Clavibacter Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241001147704 Clostridium puniceum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000228437 Cochliobolus Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 241000222235 Colletotrichum orbiculare Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 240000003211 Corylus maxima Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 description 1
- 240000002495 Cucumis melo var. inodorus Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 1
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 1
- 241000990232 Curtobacterium flaccumfaciens pv. flaccumfaciens Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000235819 Cytospora Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 241000555268 Dendroides Species 0.000 description 1
- 241000042001 Diaporthe helianthi Species 0.000 description 1
- 241001645345 Diaporthe perniciosa Species 0.000 description 1
- 241000588700 Dickeya chrysanthemi Species 0.000 description 1
- 241000982871 Dickeya paradisiaca Species 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 241000935926 Diplodia Species 0.000 description 1
- 241001307140 Diplodia seriata Species 0.000 description 1
- 241001465183 Drechslera Species 0.000 description 1
- 241001465185 Drechslera avenae Species 0.000 description 1
- 241000982938 Enterobacter cancerogenus Species 0.000 description 1
- 241000982936 Enterobacter cloacae subsp. dissolvens Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 241000556426 Erwinia rhapontici Species 0.000 description 1
- 241000221787 Erysiphe Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 241000223193 Fusarium acuminatum Species 0.000 description 1
- 241000122692 Fusarium avenaceum Species 0.000 description 1
- 241000221778 Fusarium fujikuroi Species 0.000 description 1
- 241001208371 Fusarium incarnatum Species 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 241000145511 Fusarium sacchari Species 0.000 description 1
- 241000427940 Fusarium solani Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 241001620302 Glomerella <beetle> Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 101150096276 HOG1 gene Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000592938 Helminthosporium solani Species 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 241000908271 Ilyonectria destructans Species 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000611348 Leifsonia xyli subsp. xyli Species 0.000 description 1
- 240000004322 Lens culinaris Species 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 241000228457 Leptosphaeria maculans Species 0.000 description 1
- 241000557201 Leptosphaeria sacchari Species 0.000 description 1
- 241000782726 Leptosphaeria sclerotioides Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 241001135196 Leptospira noguchii Species 0.000 description 1
- 241001135198 Leptospira santarosai Species 0.000 description 1
- 241001135200 Leptospira weilii Species 0.000 description 1
- 241001116371 Leucostoma auerswaldii Species 0.000 description 1
- 241000986453 Leucostoma kunzei Species 0.000 description 1
- 241001072282 Limnanthes Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 244000108452 Litchi chinensis Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241001344133 Magnaporthe Species 0.000 description 1
- 241001344131 Magnaporthe grisea Species 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000907556 Mucor hiemalis Species 0.000 description 1
- 241001506781 Mucor piriformis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 241000906049 Musicillium theobromae Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241001597095 Mycosphaerella pyri Species 0.000 description 1
- 101150080490 NTH1 gene Proteins 0.000 description 1
- 101150040422 NTH2 gene Proteins 0.000 description 1
- 241001226034 Nectria <echinoderm> Species 0.000 description 1
- 241001149471 Nectria cinnabarina Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000083076 Neopseudocercosporella brassicae Species 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000187680 Nocardia vaccinii Species 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241001040312 Oidium mangiferae Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000157904 Paenarthrobacter ilicis Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 241000932831 Pantoea stewartii Species 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 240000004370 Pastinaca sativa Species 0.000 description 1
- 235000017769 Pastinaca sativa subsp sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000588701 Pectobacterium carotovorum Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 241001503951 Phoma Species 0.000 description 1
- 244000309636 Phoma microspora Species 0.000 description 1
- 241001245668 Phomatodes nebulosa Species 0.000 description 1
- 241001358411 Phomopsis ipomoeae-batatas Species 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000896242 Podosphaera Species 0.000 description 1
- 241001337928 Podosphaera leucotricha Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 244000141353 Prunus domestica Species 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006029 Prunus persica var nucipersica Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000017714 Prunus persica var. nucipersica Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000204715 Pseudomonas agarici Species 0.000 description 1
- 241000218934 Pseudomonas amygdali Species 0.000 description 1
- 241000218936 Pseudomonas corrugata Species 0.000 description 1
- 241000394642 Pseudomonas marginalis pv. marginalis Species 0.000 description 1
- 241000145542 Pseudomonas marginata Species 0.000 description 1
- 241000589615 Pseudomonas syringae Species 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- 241000221300 Puccinia Species 0.000 description 1
- 244000309652 Puccinia aristidae Species 0.000 description 1
- 241001123561 Puccinia coronata Species 0.000 description 1
- 241001123559 Puccinia hordei Species 0.000 description 1
- 241001409749 Puccinia malvacearum Species 0.000 description 1
- 241000928332 Puccinia melanocephala Species 0.000 description 1
- 241001304535 Puccinia purpurea Species 0.000 description 1
- 241001209434 Puccinia xanthii Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000611345 Rathayibacter iranicus Species 0.000 description 1
- 241001467568 Rathayibacter rathayi Species 0.000 description 1
- 241001467570 Rathayibacter tritici Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 101150104869 SLT2 gene Proteins 0.000 description 1
- 101100371160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TSL1 gene Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000222480 Schizophyllum Species 0.000 description 1
- 241000222481 Schizophyllum commune Species 0.000 description 1
- 101100395426 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sty1 gene Proteins 0.000 description 1
- 241000221662 Sclerotinia Species 0.000 description 1
- 241001300361 Sclerotinia borealis Species 0.000 description 1
- 241001518705 Sclerotinia minor Species 0.000 description 1
- 241000496898 Sclerotinia spermophila Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 241001533598 Septoria Species 0.000 description 1
- 244000309530 Septoria bataticola Species 0.000 description 1
- 241001597349 Septoria glycines Species 0.000 description 1
- 241000093892 Septoria helianthi Species 0.000 description 1
- 244000309630 Septoria pisi Species 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241001135258 Serratia proteamaculans Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241001539383 Slafractonia leguminicola Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 240000003829 Sorghum propinquum Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 241001279361 Stachybotrys Species 0.000 description 1
- 241001279364 Stachybotrys chartarum Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000142909 Streptomyces acidiscabies Species 0.000 description 1
- 241000958233 Streptomyces candidus Species 0.000 description 1
- 241000520738 Streptomyces intermedius Species 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150077059 TPS1 gene Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 241000722133 Tilletia Species 0.000 description 1
- 241000722093 Tilletia caries Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 244000294925 Tragopogon dubius Species 0.000 description 1
- 235000004478 Tragopogon dubius Nutrition 0.000 description 1
- 235000012363 Tragopogon porrifolius Nutrition 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 108010087472 Trehalase Proteins 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000221576 Uromyces Species 0.000 description 1
- 241001091387 Uromyces beticola Species 0.000 description 1
- 244000309584 Uromyces graminis Species 0.000 description 1
- 241001152372 Uromyces musae Species 0.000 description 1
- 241000531578 Uromyces pisi-sativi Species 0.000 description 1
- 241000221566 Ustilago Species 0.000 description 1
- 244000046332 Ustilago esculenta Species 0.000 description 1
- 241000509513 Ustilago hordei Species 0.000 description 1
- 235000015919 Ustilago maydis Nutrition 0.000 description 1
- 244000301083 Ustilago maydis Species 0.000 description 1
- 241000233791 Ustilago tritici Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 241000082085 Verticillium <Phyllachorales> Species 0.000 description 1
- 241001123669 Verticillium albo-atrum Species 0.000 description 1
- 241000020705 Verticillium alfalfae Species 0.000 description 1
- 241001123668 Verticillium dahliae Species 0.000 description 1
- 241001447693 Verticillium longisporum Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 241001133547 Xanthomonas alfalfae subsp. alfalfae Species 0.000 description 1
- 241000567083 Xanthomonas arboricola Species 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 241000589655 Xanthomonas citri Species 0.000 description 1
- 240000001781 Xanthosoma sagittifolium Species 0.000 description 1
- 235000017957 Xanthosoma sagittifolium Nutrition 0.000 description 1
- 241000204366 Xylella Species 0.000 description 1
- 241000204362 Xylella fastidiosa Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- 241001360088 Zymoseptoria tritici Species 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 241001645946 [Corynebacterium] beticola Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 235000000183 arugula Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 230000009743 cell cycle entry Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000021019 cranberries Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940023064 escherichia coli Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 244000037666 field crops Species 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 244000000004 fungal plant pathogen Species 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 235000021232 nutrient availability Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 244000080466 oignon Species 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 235000020233 pistachio Nutrition 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 235000021039 pomes Nutrition 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 235000021013 raspberries Nutrition 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 108010045348 trehalose synthase Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
- G01N2333/38—Assays involving biological materials from specific organisms or of a specific nature from fungi from Aspergillus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
- G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
- G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
- G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
Definitions
- the invention relates to methods for identifying targets for antimicrobial and antiproliferative compounds as well as methods for identifying novel compounds for treating microbial infections and cancer.
- the present invention overcomes previous shortcomings in the art by providing novel methods for identifying targets for antimicrobial and antiproliferative compounds as well as methods for identifying novel compounds for treating cancer and microbial infections.
- One aspect of the invention provides a method of identifying one or more antimicrobial molecular targets in a fungal cell and/or bacterial cell, comprising: growing the fungal cell and/or bacterial cell in vitro under infection mimetic conditions; identifying genes that are differentially regulated (i.e., upregulated or downregulated) in the fungal cell and/or bacterial cell when grown under infection mimetic conditions as compared to the fungal cell and/or bacterial cell grown in vitro under standard or clinical laboratory conditions.
- a second aspect of the invention provides a method of identifying a compound having antimicrobial activity, comprising: growing a microbe in vitro under infection mimetic conditions in the presence or absence of a test compound; and selecting a compound that reduces the growth of or kills the microbe as compared to the microbe grown in vitro under infection mimetic conditions in the absence of the compound.
- a third aspect of the invention provides a method of identifying a compound having antimicrobial activity against a microbe in a clinical sample, comprising; culturing the clinical sample or a portion of the clinical sample in vitro under conditions that mimic an infection site in the presence or absence of a test compound; selecting a compound that reduces the growth of or kills the microbe in the clinical sample as compared to the microbe grown in vitro under infection mimetic conditions in the absence of the compound.
- a fourth aspect of the invention provides a method of treating a fungal infection in an organism, comprising administering to an organism in need thereof a therapeutically effective amount of validamycin A.
- a fifth aspect of the invention provides a media that mimics conditions at an infection site in an organism.
- a sixth aspect of the invention provides a method of identifying one or more antiproliferative molecular targets in a mammalian cancer cell, comprising: growing the mammalian cancer cell in vitro under cancer mimetic conditions; identifying genes that are upregulated in the mammalian cancer cell when grown under cancer mimetic conditions as compared to the mammalian cancer cell grown in vitro under standard or clinical laboratory conditions.
- a seventh aspect of the invention provides a method of identifying a compound having antiproliferative activity, comprising: growing a mammalian cancer cell in vitro under cancer mimetic conditions in the presence or absence of a test compound; and selecting a compound that reduces the growth of or kills the mammalian cancer cell as compared to the mammalian cancer cell grown in vitro under cancer mimetic conditions in the absence of the compound.
- An eighth aspect of the invention provides a method of identifying a compound having antiproliferative activity against a mammalian cancer cell in a clinical sample, comprising: culturing the clinical sample or a portion of the clinical sample in vitro under conditions that mimic a site of cancer proliferation in the presence or absence of a test compound; and selecting a compound that reduces the growth of or kills the mammalian cancer cell in the clinical sample as compared to the mammalian cancer cell grown in vitro under cancer mimetic conditions in the absence of the compound.
- a ninth aspect of the invention provides a cancer mimetic media that mimics conditions at a site of cancer growth in a mammal.
- FIG. 1 provides evidence of a new program of gene expression in slow growth.
- Budding yeast mutant (rho 0 ) cells were synchronized in early G1 and released into the cell cycle. Genome-wide transcript levels were determined at multiple time points as cells progressing through the cell cycle by microarray analysis. Algorithms were used to identify periodic transcripts and the transcript profiles are shown by heat map. Data are expressed as logfold change/mean. White represents above the mean of expression, Gray represents below mean expression.
- Rho 0 mutant cells exhibit the normal cell cycle transcription program, as well as a new program of expression that heavily overlaps with the yeast metabolic cycle. The yeast metabolic cycle (YMC) program is not observed in wild-type cells growing in optimized conditions.
- YMC yeast metabolic cycle
- FIG. 2 shows genes in the trehalose metabolism pathway are up-regulated and oscillate strongly only in the stress conditions in S. cerevisiae.
- mRNA levels (arbitrary expression units) for 3 trehalose pathway genes (TSL1, TPS1, and NTH1) are shown over time in a cell-cycle synchronized population of cells harboring mutations that impair oxidative metabolism (dotted) and in wild-type cells (solid).
- FIG. 3 shows that cell division is severely inhibited in slow growth medium in deletion mutants.
- Equal numbers of wild-type (WT) cells and cells deleted for various genes were grown in rich media (YEP+2% (w/v) Dextrose) over night, inoculated and diluted into rich defined medium (Yeast Nitrogen Base supplemented with essential amino acids+2% (w/v) Dextrose) or in nutrient limiting defined media (Yeast Nitrogen Base supplemented with essential amino acids+3% (v/v) Glycerol/3% (v/v) Ethanol or 3% (v/v) Ethanol only) at equal concentrations and grown for 24 hours.
- Equal volumes of medium containing WT or mutant cells were then plated on YEP+2% (w/v) Dextrose plates to determine the number of viable cells. After 48 hours, colonies were counted and results shown are relative to the number of colonies observed after growth in rich medium.
- FIG. 4 shows growth of Cryptococcus neoformans is inhibited in slow growth medium but not rich medium.
- C. neoformans cells were grown in rich medium (YEP+2% (w/v) Dextrose) with 0 mM (black), 50 mM (gray), and 100 mM (dotted) concentrations of Validamycin A. Cells were counted each hour for 6 hours and relative growth per mL was assessed.
- Right panel C. neoformans cells were grown for 24 hours in PUD media and then dosed with Validamycin A.
- Cells were grown in slow growth medium (PUD) with 0 mM (black), 50 mM (gray), and 100 mM (dotted) concentrations of Validamycin A for 7 days and then counted at time intervals shown. Media was changed every 24 hours to fresh media containing the indicated concentration of drug.
- POD slow growth medium
- FIG. 5 shows Pleiotropic Drug Resistance (PDR) genes are up-regulated in metabolically crippled S. cerevisiae cells (rho 0 ).
- Synchronized rho 0 cells exhibit up-regulated expression (dashed line) of a multi-drug resistance pump (PDRS) as well as genes encoding transcription factors that control pump gene expression (PDR1, PDR3).
- PDRS multi-drug resistance pump
- PDR1, PDR3 genes encoding transcription factors that control pump gene expression
- the expression is compared to synchronized wild type (rho + ) cells (solid line).
- phrases such as “between X and Y” and “between about X and Y” should be interpreted to include X and Y.
- phrases such as “between about X and Y” mean “between about X and about Y” and phrases such as “from about X to Y” mean “from about X to about Y.”
- the transitional phrase “consisting essentially of” means that the scope of a claim is to be interpreted to encompass the specified materials or steps recited in the claim and those that do not materially affect the basic and novel characteristic(s) of the claimed invention. Thus, the term “consisting essentially of” when used in a claim of this invention is not intended to be interpreted to be equivalent to “comprising.”
- the terms “increase,” “increasing,” “increased,” “enhance,” “enhanced,” “enhancing,” and “enhancement” (and grammatical variations thereof) describe an elevation of at least about 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, 500% or more as compared to a control.
- the terms “reduce,” “reduced,” “reducing,” “reduction,” “diminish,” and “decrease” describe, for example, a decrease of at least about 5%, 10%, 15%, 20%, 25%, 35%, 50%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% as compared to a control.
- the reduction can result in no or essentially no (i.e., an insignificant amount, e.g., less than about 10% or even 5%) detectable activity or amount.
- an “antimicrobial molecular target” as used herein means a molecular target (nucleic acid, polypeptide) for an antimicrobial compound.
- infection mimetic conditions are conditions designed to mimic those found in or on an infected host (e.g., an animal, a plant) such as, for example, conditions of low nutrient, high/low temperature, high/low osmotic potential (high/low salt); high/low humidity, high/low pH, high/low oxygen and that do not support an optimal rate of cell division for any given fungal cell or bacterial cell; that is, conditions that mimic conditions encountered by the organism during infection.
- infected host e.g., an animal, a plant
- Each parameter for an infection mimetic condition is identical to or is within at least about 20% (e.g., about 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%) of the same parameter at a given infection site.
- Infection mimetic conditions are thus suboptimal conditions when compared to the optimal laboratory conditions provided for growth of fungal cells and/or bacterial cells.
- Infection mimetic conditions include variance in any of the conditions noted above, e.g., variance in temperature as experienced by an organism during daylight/nighttime hours.
- infection mimetic conditions can be any conditions in which the fungal cell or bacterial cell grows at a lower rate than it grows when placed under standard laboratory conditions that are generally developed to optimize cell growth rate to increase rapidity of experimental/analytical processes.
- the infection mimetic conditions provide growth rates for a bacterium or a fungus that are reduced by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%
- antiproliferative molecular target means a molecular target (nucleic acid, polypeptide) for an antiproliferative compound.
- cancer mimetic conditions means conditions designed to mimic those found at the site of cancer proliferation in a mammal including but not limited to conditions of low nutrient, limited growth factors, high/low temperature, high/low osmotic potential (high/low salt), high/low humidity, high/low pH, high/low oxygen, increased lactate, altered extracellular matrix, and that do not support an optimal rate of cell division for any given mammalian cancer cell; that is, conditions that mimic conditions encountered by the cancer cell during proliferation. Cancer mimetic conditions are thus suboptimal conditions when compared to the optimal laboratory conditions provided for growth of mammalian cancer cells.
- cancer mimetic conditions include the tumor microenvironment and/or the intratumoral environment for solid tumors and circulating blood for blood cell cancers.
- Each parameter for a cancer mimetic condition is identical to or is within at least about 20% (e.g., about 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%) of the same parameter at a given site of cancer proliferation.
- cancer mimetic conditions can be any conditions in which a cancer cell grows at a lower rate than it grows when placed under standard laboratory conditions that are generally developed to optimize cell growth rate to increase rapidity of experimental/analytical processes.
- the cancer mimetic conditions provide growth rates for cancer cells that are reduced by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%
- standard laboratory conditions or “clinical laboratory conditions” are conditions designed to optimize the growth and cell division of an organism or a cancer cell by providing optimal nutrients, temperature, pH, osmotic potential, oxygen, water/humidity; that is, the conditions that provide the optimal rate of cell division and growth for any given fungal cell, bacterial cell or cultured mammalian cancer cell.
- Optimized growth conditions are those used for culture of organisms in a laboratory setting. Conditions are generally developed to optimize cell growth rate to increase rapidity of experimental/analytical processes. While conditions used may not provide the environment for maximal growth rates, they are substantially more favorable than conditions encountered by the cell during growth in the infection mimetic environment
- the present invention is directed in part to novel methods for screening compounds for antimicrobial and antiproliferative activity.
- the assumption underlying prior known standard screening processes and protocols is that a finding that compounds that fail to exhibit activity against pathogens in these in vitro environments is conclusive as to whether the same molecules will show activity in vivo.
- the question of whether this assumption is justified or not has rarely been posed, let alone carefully investigated.
- standard approaches based on this assumption have successfully identified a variety of anti-microbial and anti-proliferative drugs, it is clear from our recent research findings that a variety of important drugs and drug targets are missed in primary screens.
- Protocols of this type have also been standardized for assessing antibiotic sensitivity in clinical settings, so that the proper antibiotic can be used to treat an infection [1].
- a further benefit of standardized protocols is the ability to directly compare the relative efficacy of various drugs while holding the environmental conditions constant.
- the central issue facing current standardized screening methods is that the growth conditions are optimized for rapid growth, and these optimized growth conditions are far from what are encountered by pathogenic organisms living in a host.
- infected tissues do not provide the pathogen with the high levels of sugars (e.g. 2% w/v/dextrose), proteins, and micronutrients available in the rich media formulas used for in vitro growth.
- pathogens are likely to encounter additional stresses such as high temperatures, due to fever, a dynamic osmotic environment, as well as attacks from the immune system.
- GRR low nutrients
- Stress Response Genes Stress Response Genes
- YMC Yeast Metabolic Cycle
- a first aspect of the invention provides a method of identifying one or more antimicrobial molecular targets in a fungal cell and/or bacterial cell, comprising: growing the fungal cell and/or bacterial cell in vitro under infection mimetic conditions; identifying genes that are differentially expressed (i.e., upregulated or downregulated) in the fungal cell and/or bacterial cell when grown under infection mimetic conditions as compared to the fungal cell and/or bacterial cell grown in vitro under standard or clinical laboratory conditions.
- the growth conditions can mimic conditions at a site of an infection by a fungal or bacterial cell (i.e., infection mimetic conditions).
- a second aspect of the invention provides a method of identifying a compound having antimicrobial activity, comprising: growing a microbe (e.g., bacterium or fungus) in vitro under infection mimetic conditions in the presence or absence of a test compound; and selecting a compound that reduces the growth of (e.g., reduces the rate of cell division) or kills the microbe as compared to the microbe grown in vitro under infection mimetic conditions in the absence of the compound.
- a microbe e.g., bacterium or fungus
- a third aspect of the invention provides a method of identifying a compound having antimicrobial activity against a microbe (i.e., bacterium or fungus) in a clinical sample, comprising culturing the clinical sample or a portion of the clinical sample in vitro under conditions that mimic an infection site in the presence or absence of a test compound; selecting a compound that reduces the growth of (e.g., reduces the rate of cell division) or kills the microbe in the clinical sample as compared to the microbe grown in vitro under infection mimetic conditions in the absence of the compound.
- the infection site can be where the clinical sample was obtained or the clinical sample can be obtained from a different site.
- Microbes are bacteria and/or fungi as described herein.
- a clinical sample can be prepared by removing a portion of tissue from a patient/subject and culturing the portion of tissue or other sample on a plate or in a dish in an infection mimetic medium, wherein the growth conditions provided by the infection mimetic media (e.g., temperature, pH, nutrients, etc) mimic those in the infected host organism, for example at the site of infection in the infected organism.
- the infection mimetic media e.g., temperature, pH, nutrients, etc
- a clinical sample may be obtained by any method known in the art, such as surgery, biopsy, lavage, aspiration, etc.
- the sample may be a bodily fluid, e.g., blood, serum, plasma, saliva, urine, cerebrospinal fluid, perspiration, etc.
- upregulation of a gene means an increase in expression (i.e., mRNA levels) by that gene of at least about 5% to about 500% or more as compared to a control (e.g., expression levels of the same gene when not grown under infection mimetic or cancer mimetic conditions).
- upregulation of a gene means an increase in mRNA levels of at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%
- upregulation of a gene means an increase in mRNA levels of at least about 10% to about 500%, about 10% to about 450%, about 10% to about 400%, about 10% to about 350%, about 10% to about 300%, about 10% to about 250%, about 10% to about 200%, about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 20% to about 500%, about 20% to about 450%, about 20% to about 400%, about 20% to about 350%, about 20% to about 300%, about 20% to about 250%, about 20% to about 200%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 60%, about 30% to about 500%, about 30% to about 450%, about 30% to about 400%, about 30% to about 350%, about 30% to about 300%, about 30% to about 250%, about 30% to about 200%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 60%, about 50% to about 500%, about 50% to about 450%, about 50% to
- down-regulation of a gene means a decrease in expression (i.e., mRNA levels) by that gene of at least about 5% to about 100% compared to a control (e.g., expression levels of the same gene when not grown under infection mimetic or cancer mimetic conditions).
- downregulation of a gene means a decrease in mRNA levels of at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%,
- downregulation of a gene means a decrease in mRNA levels of at least about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 15% to about 100%, about 15% to about 90%, about 15% to about 80%, about 15% to about 70%, about 15% to about 60%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 40% to about 100%, about 50% to about 100%, and the like.
- the level of downregulation or decrease in mRNA expression can vary depending on the organism and/or the particular gene.
- a compound can reduce the growth or the rate of cell division of the organism by at least about 5% to about 100% as compared to a control.
- the growth or the rate of cell division of an organism can be reduced by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%
- the rate of growth or the rate of cell division of an organism can be reduced by at least about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 15% to about 100%, about 150% to about 90%, about 15% to about 80%, about 15% to about 70%, about 15% to about 60%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 40% to about 100%, about 50% to about 100%, and the like.
- the reduction in growth can vary depending on the organism and/or the compound being tested.
- the site of infection can be in an animal, optionally a mammal, an avian, a reptile, a fish, an amphibian, or an insect.
- a mammal can include but is not limited to a human, non-human primate (e.g., gorilla, monkey, baboon, and chimpanzee, etc.), dog, cat, goat, horse, pig, cow, sheep, and the like, or a laboratory animal (e.g., rats, guinea pigs, mice, gerbils, hamsters, and the like).
- an avian can include but is not limited to a chicken, duck, turkey, goose, quail, pheasant, or a bird kept as a pet (e.g., parakeets, parrots, macaws, cockatoos, canaries, and the like). Both male and female animals and animals of any age are suitable, including embryonic (e.g., in utero or in ovo), infant, juvenile, adolescent, adult and geriatric animals.
- the site of infection can be in a mammal, optionally a human.
- the site of infection can be in a mammal and the infection mimetic conditions can mimic, for example, cerebral spinal fluid, blood, epidermal surface, mucosal surface (eye, mouth, intestine, genital tract, nasal tract), lung surface, brain tissue, bladder, kidney, a wound, and/or other organ or tissue.
- the infection mimetic conditions can mimic, for example, cerebral spinal fluid, blood, epidermal surface, mucosal surface (eye, mouth, intestine, genital tract, nasal tract), lung surface, brain tissue, bladder, kidney, a wound, and/or other organ or tissue.
- Exemplary conditions that mimic fungal meningitis infection in cerebral spinal fluid can include normal sodium levels, increased temperature (e.g., fever), low carbohydrate, elevated pH, and low nitrogen and exemplary conditions mimicking a microbial wound site can include low sodium levels, elevated temperature, elevated pH and low nitrogen.
- Exemplary cancer mimetic mimetic conditions for media of this invention are provided in Table 1.
- infection mimetic conditions can be any conditions in which the fungal cell or bacterial cell grows or divides at a lower rate than when placed under standard laboratory conditions that are generally developed to optimize cell growth rate to increase rapidity of experimental/analytical processes.
- An exemplary medium designed for reduced growth and reduced cell division in a bacterium or a fungus includes, for example, a medium comprising Yeast Nitrogen Base supplemented with essential amino acids and either 3% (v/v) Glycerol/3% (v/v) Ethanol or 3% Ethanol (v/v) only.
- a fungal cell or a bacterial cell can be from any fungal genera or bacterial genera that can cause disease and infection (i.e., pathogenic) in an animal (e.g., in a mammal, an avian, a reptile, a fish, an amphibian, or an insect).
- Non-limiting examples of bacterial pathogens include Bacillus spp., Bordetella spp., Brucella spp., Borrellia spp., Campylobacter spp., Chlamydia spp., Clostridium spp., Corynebacterium spp., Enteroccocus spp., Escherichia spp., Haemophilus spp., Helicobacter spp., Legionella spp., Leptospira spp., Listeria spp., Mycobacterium spp., Mycoplasma spp., Neisseria spp., Psuedomonas spp., Rickettsia spp., Salmonella spp., Shigella spp., Staphylococcus spp., Streptococcus spp., Vibrio spp., or Yersinia
- bacterial species useful with this invention include, but are not limited to, Bacillus anthracis, Bacillus cereus, Bordetella pertussis, Brucella abortus, Brucella canis, Brucella melitensis, Borrelia burgdorferi, Borrelia garinii, Borrelia afzelii, Borrelia recurrentis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheriae, Enteroccocus faecilis, Enteroccocus faecium, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Legionella pneumophila, Leptospira interrogans, Leptospira santarosai,
- Non-limiting examples of an animal fungal pathogen include Cryptococcus spp., Candida spp., Mucor spp., Aspergillus spp., Histoplasma spp, Pneumocytis spp., or Stachybotrys spp.
- fungal species useful with this invention include, but are not limited to, Cryptococcus neoformans, Candida albicans, Candida tropicalis, Mucor circinelloides, Aspergillus fumigatus Histoplasma capsulatum, Pneumocytis jirovecii, Trichophyton spp., Epidermophyton spp., Microsporum spp, or Tinea spp.
- the fungal cell can be a cell from Cryptococcus neoformans, Candida albicans, Candida tropicalis, Mucor circinelloides, and/or Aspergillus fumigatus.
- the site of infection can be in a mammal and infection mimetic conditions can mimic cerebral spinal fluid.
- a method of identifying one or more antimicrobial molecular targets in a fungal cell or a bacterial cell comprising: growing the fungal cell or bacterial cell in vitro under infection mimetic conditions that mimic cerebral spinal fluid; identifying genes that are differentially regulated in the fungal cell or bacterial cell when grown under infection mimetic conditions as compared to the fungal cell or bacterial cell grown in vitro under standard or clinical laboratory conditions, wherein the conditions that mimic cerebral spinal fluid comprise a medium comprising phosphate buffered saline (PBS), urea (5 g/L) and 0.1% (w/v) dextrose.
- PBS phosphate buffered saline
- urea 5 g/L
- the fungal cell can be Cryptococcus spp., optionally Cryptococcus neoformans.
- the standard laboratory conditions that support rapid cell division can comprise a media comprising yeast extract peptone dextrose (YEPD) with 2% (w/v) dextrose.
- a method of identifying a compound having antimicrobial activity comprising: growing a fungus or bacterium in vitro under infection mimetic conditions that mimic cerebral spinal fluid in the presence or absence of a test compound; and selecting a compound that reduces the growth of or kills the fungus or bacterium as compared to the fungus or bacterium grown in vitro under infection mimetic conditions in the absence of the compound, wherein the conditions that mimic cerebral spinal fluid comprise a medium comprising phosphate buffered saline (PBS), urea (5 g/L) and 0.1% (w/v) dextrose.
- the fungal cell is Cryptococcus spp., optionally Cryptococcus neoformans.
- a method of identifying a compound having antimicrobial activity against a fungus or a bacterium in a clinical sample comprising culturing the clinical sample or a portion of the clinical sample in vitro under conditions that mimic an infection site in the presence or absence of a test compound, wherein the conditions that mimic an infection site mimic cerebral spinal fluid; selecting a compound that reduces the growth of or kills the fungus or a bacterium in the clinical sample as compared to the fungus or a bacterium grown in vitro under infection mimetic conditions in the absence of the compound, wherein the conditions that mimic cerebral spinal fluid can comprise low nitrogen and low carbohydrate.
- a condition that mimics cerebral spinal fluid can comprise a medium comprising phosphate buffered saline (PBS), urea (5 g/L) and 0.1% (w/v) dextrose.
- PBS phosphate buffered saline
- urea 5 g/L
- the fungal cell can be Cryptococcus spp., optionally Cryptococcus neoformans.
- the infection site can be where the clinical sample was obtained or the clinical sample can be obtained from a different site.
- Exemplary optimal growth media for budding yeast and other microbes can include, but is not limited to, (1) YEP medium comprising 10 g yeast extract, 10 g Bacto peptone, 5 g NaCl in a total volume of 1 L of water, pH to 7.0) and 2% (w/v) dextrose; (2) yeast nitrogen base (YNB) medium supplemented with essential amino acids, 2% (w/v) dextrose and either: (i) 3% glycerol/3% ethanol (v/v) or (ii) 3% ethanol (v/v); (3) yeast extract peptone dextrose (YEPD) medium comprising yeast extract peptone dextrose and 2% (w/v) dextrose.
- YEP medium comprising 10 g yeast extract, 10 g Bacto peptone, 5 g NaCl in a total volume of 1 L of water, pH to 7.0
- yeast nitrogen base (YNB) medium supplemented with essential amino acids
- the site of infection can be in or on a plant and the infection mimetic conditions can mimic conditions on a plant surface (leaf, stem, flower, root, fruit), in phloem, in xylem, or within and/or between a plant's cells (i.e., intracellular and/or intercellular), and/or in or on other plant tissue types.
- the site of infection can be in or on a plant and the infection mimetic conditions can mimic conditions in the soil.
- the conditions on a plant surface (e.g., leaf surface, stem surface, petal surface, and the like) at the time of bacterial or fungal infection can be the conditions at the site of infection that are mimicked as disclosed herein.
- these conditions can vary based on the plant species as well as where the plant is located (that is, the environment in which the plant is growing—e.g., macroenvironment).
- the environment around the plant will have an impact on the choice of conditions to be mimicked.
- a plant can be growing, for example, under a high humidity to low humidity conditions, high heat to low heat conditions, high light to low light conditions, or conditions of drought to flood conditions, and the like.
- the conditions that a fungal pathogen or a bacterial pathogen may experience on the surface of a plant can be a combination of the effects of microenvironment and the macroenvironment.
- a bacterial pathogen or a fungal on the surface of plant and prior to entry into the plant will likely find conditions of low nutrient availability (e.g., low nitrogen and/or low carbohydrate levels) on the plant surface.
- the humidity may be low due to dry surrounding conditions.
- the plant can include, but is not limited to, an angiosperm, a gymnosperm, a bryophyte, a fern and/or fern ally.
- the plant can be a cell, plant and/or plant part of any plant species.
- Non-limiting examples of plants useful with the methods of the present invention include turf grasses, vegetable crops, including artichokes, kohlrabi, arugula, leeks, asparagus, lettuce (e.g., head, leaf, romaine), malanga, melons (e.g., muskmelon, watermelon, crenshaw, honeydew, cantaloupe), cole crops (e.g., brussels sprouts, cabbage, cauliflower, broccoli, collards, kale, chinese cabbage, bok choy), cardoni, carrots, napa, okra, onions, celery, parsley, chick peas, parsnips, chicory, peppers, potatoes, cucurbits (e.g., marrow, cucumber, zucchini, squash, pumpkin), radishes, dry bulb onions, rutabaga, eggplant, salsify, escarole, shallots, endive, garlic, spinach, green onions, squash, greens, beet (su
- a fungal cell or a bacterial cell can be from any fungal genera or bacterial genera that can cause disease and infection (i.e., is pathogenic) in a plant.
- fungal plant pathogens include Alternaria spp., Aspergillus spp., Botryodiplodia spp., Botrytis spp., Cercospora spp., Cladosporium spp., Clavoceps spp., Cochliobolus spp., Colletotrichum spp., Diaporthe spp., Diplodia spp., Drechslera spp., Erysiphe spp., Fusarium spp., Gibberella spp., Glomerella spp., Helminthosporium spp., Leptosphaeria spp., Leucostoma spp., Magnaporthe spp., Mucor
- plant pathogenic fungal species useful with this invention include, but are not limited to, Alternaria brassicola, Alternaria dianthi, Alternaria alternata, Alternaria raphani, Aspergillus niger, Botryodiplodia umicola, Botryodiplodia ocidii, Botrytis cinerea, Botrytis fabae, Botrytis narcissicola, Cercospora apii, Cercospora beticola, Cercospora kikuchii, Cladosporium arthropodii, Cladosporium cladosporoides, Clavoceps purpurea, Cochliobolus carbonum, Cochliobolus sativus, Colletotrichum glycines, Colletotrichum orbiculare, Colletotrichum pisi, Colletotrichum trifoli, Diaporthe helianthi, Diaporthe perniciosa, Diaporthe phaeolorum
- Non-limiting examples of bacterial plant pathogens include Acetobacter spp., Agrobacterium spp., Arthrobacter spp., Bacillus spp., Clavibacter spp., Clostridium spp., Corynebacterium spp., Erwinia spp., Nocardia spp., Pseudomonas spp., Serratia spp., Streptomyces spp., Xanthomonas spp., or Xylella spp.
- species of plant pathogenic bacteria useful with this invention include, but are not limited to, Acetobacter aceti, Acetobacter pasteurianus, Agrobacterium radiobacter, Agrobacterium rhizogenes, Agrobacterium rubi, Agrobacterium tumefaciens, Arthrobacter ilicis, Bacillus megaterium, Bacillus pumilus, Clavibacter iranicus, Clavibacter rathayi, Clavibacter tritici, Clavibacter xyli, Clostridium puniceum, Corynebacterium beticola, Corynebacterium flaccumfaciens, Corynebacterium michiganensis, Erwinia chrysanthemi, Erwinia paradisiaca, Erwinia cancerogena, Erwinia dissolvens, Erwinia carotovora, Erwinia herbicola, Erwinia pyrofoliae, Erwinia rhapontici, Erwini
- media that mimic conditions at an infection site in an organism can mimic conditions of cerebral spinal fluid, blood, epidermal surface, mucosal surface (eye, mouth, intestine, genital tract, nasal tract), lung surface, brain tissue, bladder, kidney, wound, or other organ or tissue, and the conditions can mimic cerebral spinal fluid, blood, epidermal surface, mucosal surface (eye, mouth, intestine, genital tract, nasal tract), lung surface, brain tissue, bladder, kidney, a wound, and/or other organ or tissue.
- the invention provides media that mimics cerebral spinal fluid comprising low nitrogen and low carbohydrate (e.g., low glucose).
- the media that mimic conditions at an infection site can mimic conditions on a plant surface (leaf, stem, flower, root, fruit), in phloem, in xylem, or within and/or between a plant's cells (i.e., intracellular and/or intercellular), and/or in or on other plant tissue types.
- the media that mimic conditions at an infection site can mimic conditions in the soil.
- the invention further provides a method of treating a fungal infection in an organism, comprising administering to an organism in need thereof a therapeutically effective amount of validamycin A.
- the organism can be an animal and the fungal infection can be caused by Cryptococcus spp., Candida spp., Mucor spp., and/or Apergillus spp, optionally the fungal infection can be caused by Cryptococcus neoformans, Candida albicans, Candida tropicalis, Mucor circinelloides, and/or Aspergillus fumigatus.
- the organism can be a plant and the fungal infection is not caused by Rhizoctonia spp., optionally not by Rhizoctonia solani.
- the plant is not rice and the fungal infection is not caused by Rhizoctonia spp., optionally not by Rhizoctonia solani.
- An additional aspect of the invention provides a method of identifying one or more antiproliferative molecular targets in a mammalian cancer cell, comprising: growing the mammalian cancer cell in vitro under cancer mimetic conditions; identifying genes that are upregulated in the mammalian cancer cell when grown under cancer mimetic conditions as compared to the mammalian cancer cell grown in vitro under standard or clinical laboratory conditions.
- a further aspect of the invention provides a method of identifying a compound having antiproliferative activity, comprising: growing a mammalian cancer cell in vitro under cancer mimetic conditions in the presence or absence of a test compound; and selecting a compound that reduces the growth of (e.g., reduce the rate of cell division) or kills the mammalian cancer cell as compared to the mammalian cancer cell grown in vitro under cancer mimetic conditions in the absence of the compound.
- a still further aspect of the invention provides a method of identifying a compound having antiproliferative activity against a mammalian cancer cell in a clinical sample, comprising culturing the clinical sample or a portion of the clinical sample in vitro under conditions that mimic a site of cancer proliferation in the presence or absence of a test compound; and selecting a compound that reduces the growth of (e.g., reduce the rate of cell division) or kills the mammalian cancer cell in the clinical sample as compared to the mammalian cancer cell grown in vitro under cancer mimetic conditions in the absence of the compound.
- a clinical sample can be prepared by removing a portion of tissue from a patient/subject and culturing the portion of tissue on a plate or in a dish in a cancer mimetic medium, wherein the growth conditions provided by the cancer mimetic media (e.g., temperature, pH, nutrients, etc) mimic those in the organism, for example at the site of cancer proliferation in the organism.
- the cancer mimetic media e.g., temperature, pH, nutrients, etc
- An exemplary mammalian cancer cell includes a carcinoma cell, sarcoma cell, lymphoma cell, leukemia cell, or germinoma cell.
- the mammalian cancer cell includes, but is not limited to, a pancreatic cancer cell, liver cancer cell, colon cancer cell, breast cancer cell, cervical cancer cell, vaginal cancer cell, testicular cancer cell, skin cancer cell, prostate cancer cell, mouth cancer cell, bone cancer cell, esophageal cancer cell, lymphoma cell, leukemia cell, lung cancer cell, colon cancer cell, rectal cancer cell, kidney cancer cell, brain cancer cell, and gastric cancer cell.
- the growth conditions for the mammalian cancer cell mimic conditions at a site of cancer proliferation (i.e., cancer mimetic conditions).
- the site of cancer proliferation can be, but is not limited to, blood, pancreas, liver, colon, breast, cervix, vagina, testicle, skin, prostate, lymph node, lung, rectum, esophagus, mouth, bone, colon, kidney, brain, stomach, a wound and/or other organ or tissue.
- the clinical sample can be obtained from the site of cancer proliferation or it can be obtained from another site in/on the organism.
- the growth conditions for the mammalian cancer cell mimic conditions at, for example, the site of solid tumors and/or leukemias/lymphomas in blood, pancreas, liver, colon, breast, cervix, vagina, testicle, skin, prostate, lymph node, lung, rectum, esophagus, mouth, bone, colon, kidney, brain, stomach, a wound, and/or other organ or tissue.
- the site of cancer proliferation can be the stomach, wherein the cancer cell is a stomach cancer cell, and the cancer mimetic conditions comprise a media comprising high pH, Heliobacter pylori infection, low oxygen, and restricted nutrients.
- the invention further provides a cancer mimetic media that mimics conditions at a site of cancer growth in a mammal.
- a cancer mimetic condition for a solid tumor can include, for example, low sodium, low oxygen (e.g., hypoxic), low carbohydrate, and low available nitrogen.
- a cancer mimetic condition for a blood cancer, lymphoma or leukemia can include, for example, normal sodium levels, increased temperature (e.g., fever), low carbohydrate, elevated pH, and low nitrogen. See, Table 1 for exemplary infection mimetic conditions for media of this invention.
- GRR low nutrients
- Stress Response Genes Stress Response Genes
- YMC Yeast Metabolic Cycle
- FIG. 1 Two distinct and coupled cycling programs of gene expression were identified in cells growing in rho 0 mutant cells that were growing slowly. Using algorithms to identify periodic behaviors, we identified two distinct sets of oscillatory programs. These two programs are depicted in FIG. 1 .
- the cell cycle oscillation depicted on the lower left is common to cells growing in optimized or nutrient non-limiting conditions.
- the metabolic oscillations on the lower right are found only in metabolic mutants or in cells in limiting nutrient conditions.
- the trehalose pathway may be one important connection between the cell cycle clock and the YMC, and may be a pathway that is essential for cell division in metabolic mutants or in nutrient-limited media.
- screening conditions that are optimized for speed and cost often bear little resemblance (if any) to the conditions encountered by cells during the infection of a human host.
- CSF cerebral spinal fluid
- yeast cells grow and divide in the cerebral spinal fluid (CSF) of infected patients.
- CSF is low in glucose and nitrogen, and during infection, the host temperature is elevated, leading to slow division of the yeast cells [13].
- the standardized primary in vitro screening conditions i.e., standard laboratory conditions
- the growth conditions encountered by the yeast cells during infection are very different than those encountered in standardized screening protocols.
- the inventors have discovered that the transcriptional activation or repression of some fraction of the genes controlling the cell cycle is important for cell division in the face of limiting nutrients or stress, that is, the activation or repression of this fraction of genes is important when the organism enters in the slow growth mode. Furthermore, most of the conditions likely to be encountered by microbes attempting to divide in a host during an infection scenario are sub-optimal and force cells to divide slowly. The same appears to be true for tumor cells growing in a solid tumor lacking an adequate blood supply. Genes in pathways important for division in sub-optimal growth conditions represent viable drug targets for anti-microbial or anti-proliferative compounds targeted at the organisms whose slow growth programs involve expression of these genes.
- a trehalose-mimetic compound (Validamycin A) produced by a Streptomyces bacterium, could target the trehalose pathway in S. cerevisiae and in C. neoformans, and inhibit their cell division in sub-optimal growth conditions.
- Validamycin A had no effect on division rates in optimal growth conditions (YEPD+2% (w/v) Dextrose), but severely inhibited division rates in slow growth conditions (PUD medium; PBS, 5g/L Urea, supplemented with 0.1% (w/v) dextrose was used, which mimics nutrient conditions in cerebral spinal fluid) ( FIG. 4 ).
- PBS 5g/L Urea, supplemented with 0.1% (w/v) dextrose was used, which mimics nutrient conditions in cerebral spinal fluid
- Plating assays indicate that Validamycin A is fungicidal in these conditions, as colony forming units are substantially reduced when cells are exposed to Validamycin A under slow growth conditions.
- genes such as SFG1 genes such as SFG1
- the protection of cellular components from stresses induced by metabolic pathways specific to slow growth including oxidative and osmotic stresses
- genes such as HOG1 and SLT2, and Rad53 genes such as SFG1 and SLT2, and Rad53.
- Sfgl When mutated, the gene encoding Sfgl has a phenotype similar (but not identical) to the trehalose pathways. Mutant cells where the Sfg1 gene has been deleted (sfgl ⁇ ) exhibit a more rapid division rate than wild-type cells in optimal growth conditions, but are severely impaired for division in sub-optimal growth conditions.
- Trehalose has been shown to be an important molecule for the growth and virulence of pathogenic bacteria in the genus Mycobacteria, including Mycobacterium tuberculosis.
- Mycobacteria in general are extremely slow growing and often refractory to antibiotic treatments. It is not clear whether trehalose pathways are part of a slow-division pathway in Mycobacteria, but these findings suggest that genetic pathways essential for slow division may exist in bacterial species in addition to fungi. Thus, the application of our infection mimetic growth conditions to bacterial species may yield new insights into novel antibiotic targets [28].
- Pleiotropic Drug Resistance (PDR) genes are up-regulated in metabolically crippled S. cerevisiae cells(rho 0 ).
- Synchronized rho 0 cells exhibit up-regulated expression (dashed line) of a multi-drug resistance pump (PDRS) as well as genes encoding transcription factors that control pump gene expression (PDR1, PDR3).
- PDRS multi-drug resistance pump
- PDR1, PDR3 transcription factors that control pump gene expression
Abstract
The invention is directed to methods for identifying targets for antimicrobial and antiproliferative compounds as well as methods for identifying novel compounds for treating cancer and microbial infections.
Description
- This application is a divisional application of U.S. patent application Ser. No. 15/572,899, filed on Nov. 9, 2017, which is a 35 U.S.C. § 371 national phase application of International Application Serial No. PCT/US2016/031712, filed May 11, 2016, which claims the benefit of U.S. Provisional Application No. 62/179,545, filed May 11, 2015, the entire contents of each of which is incorporated herein by reference.
- The invention relates to methods for identifying targets for antimicrobial and antiproliferative compounds as well as methods for identifying novel compounds for treating microbial infections and cancer.
- There are a variety of approaches for discovering antimicrobial or antiproliferative compounds that range from identifying specific drug targets and then designing chemical agents to attack these targets (so-called ‘rational’ drug design), or by pharmacological screening of libraries of chemical compounds that have a desired chemotherapeutic effect (e.g., antimicrobials that kill a specific disease causing organism). Whether screening genetic pathways for novel drug targets, or screening compound libraries for pharmacological activity, the initial screening conditions constrain the targets or compounds to a smaller subset that will be analyzed further. For reasons of safety and practicality these initial screening steps are always performed in vitro. Successfully identifying potential compounds during the primary in vitro screening process is critical, as any putative drug or drug target that does not make it through this screen will not be evaluated further in an in vivo system.
- The present invention overcomes previous shortcomings in the art by providing novel methods for identifying targets for antimicrobial and antiproliferative compounds as well as methods for identifying novel compounds for treating cancer and microbial infections.
- One aspect of the invention provides a method of identifying one or more antimicrobial molecular targets in a fungal cell and/or bacterial cell, comprising: growing the fungal cell and/or bacterial cell in vitro under infection mimetic conditions; identifying genes that are differentially regulated (i.e., upregulated or downregulated) in the fungal cell and/or bacterial cell when grown under infection mimetic conditions as compared to the fungal cell and/or bacterial cell grown in vitro under standard or clinical laboratory conditions.
- A second aspect of the invention provides a method of identifying a compound having antimicrobial activity, comprising: growing a microbe in vitro under infection mimetic conditions in the presence or absence of a test compound; and selecting a compound that reduces the growth of or kills the microbe as compared to the microbe grown in vitro under infection mimetic conditions in the absence of the compound.
- A third aspect of the invention provides a method of identifying a compound having antimicrobial activity against a microbe in a clinical sample, comprising; culturing the clinical sample or a portion of the clinical sample in vitro under conditions that mimic an infection site in the presence or absence of a test compound; selecting a compound that reduces the growth of or kills the microbe in the clinical sample as compared to the microbe grown in vitro under infection mimetic conditions in the absence of the compound.
- A fourth aspect of the invention provides a method of treating a fungal infection in an organism, comprising administering to an organism in need thereof a therapeutically effective amount of validamycin A.
- A fifth aspect of the invention provides a media that mimics conditions at an infection site in an organism.
- A sixth aspect of the invention provides a method of identifying one or more antiproliferative molecular targets in a mammalian cancer cell, comprising: growing the mammalian cancer cell in vitro under cancer mimetic conditions; identifying genes that are upregulated in the mammalian cancer cell when grown under cancer mimetic conditions as compared to the mammalian cancer cell grown in vitro under standard or clinical laboratory conditions.
- A seventh aspect of the invention provides a method of identifying a compound having antiproliferative activity, comprising: growing a mammalian cancer cell in vitro under cancer mimetic conditions in the presence or absence of a test compound; and selecting a compound that reduces the growth of or kills the mammalian cancer cell as compared to the mammalian cancer cell grown in vitro under cancer mimetic conditions in the absence of the compound.
- An eighth aspect of the invention provides a method of identifying a compound having antiproliferative activity against a mammalian cancer cell in a clinical sample, comprising: culturing the clinical sample or a portion of the clinical sample in vitro under conditions that mimic a site of cancer proliferation in the presence or absence of a test compound; and selecting a compound that reduces the growth of or kills the mammalian cancer cell in the clinical sample as compared to the mammalian cancer cell grown in vitro under cancer mimetic conditions in the absence of the compound.
- A ninth aspect of the invention provides a cancer mimetic media that mimics conditions at a site of cancer growth in a mammal.
- These and other aspects of the invention are set forth in more detail in the description of the invention below.
-
FIG. 1 provides evidence of a new program of gene expression in slow growth. Budding yeast mutant (rho0) cells were synchronized in early G1 and released into the cell cycle. Genome-wide transcript levels were determined at multiple time points as cells progressing through the cell cycle by microarray analysis. Algorithms were used to identify periodic transcripts and the transcript profiles are shown by heat map. Data are expressed as logfold change/mean. White represents above the mean of expression, Gray represents below mean expression. Rho0 mutant cells exhibit the normal cell cycle transcription program, as well as a new program of expression that heavily overlaps with the yeast metabolic cycle. The yeast metabolic cycle (YMC) program is not observed in wild-type cells growing in optimized conditions. -
FIG. 2 shows genes in the trehalose metabolism pathway are up-regulated and oscillate strongly only in the stress conditions in S. cerevisiae. mRNA levels (arbitrary expression units) for 3 trehalose pathway genes (TSL1, TPS1, and NTH1) are shown over time in a cell-cycle synchronized population of cells harboring mutations that impair oxidative metabolism (dotted) and in wild-type cells (solid). -
FIG. 3 shows that cell division is severely inhibited in slow growth medium in deletion mutants. Equal numbers of wild-type (WT) cells and cells deleted for various genes were grown in rich media (YEP+2% (w/v) Dextrose) over night, inoculated and diluted into rich defined medium (Yeast Nitrogen Base supplemented with essential amino acids+2% (w/v) Dextrose) or in nutrient limiting defined media (Yeast Nitrogen Base supplemented with essential amino acids+3% (v/v) Glycerol/3% (v/v) Ethanol or 3% (v/v) Ethanol only) at equal concentrations and grown for 24 hours. Equal volumes of medium containing WT or mutant cells were then plated on YEP+2% (w/v) Dextrose plates to determine the number of viable cells. After 48 hours, colonies were counted and results shown are relative to the number of colonies observed after growth in rich medium. -
FIG. 4 shows growth of Cryptococcus neoformans is inhibited in slow growth medium but not rich medium. Left panel: C. neoformans cells were grown in rich medium (YEP+2% (w/v) Dextrose) with 0 mM (black), 50 mM (gray), and 100 mM (dotted) concentrations of Validamycin A. Cells were counted each hour for 6 hours and relative growth per mL was assessed. Right panel: C. neoformans cells were grown for 24 hours in PUD media and then dosed with Validamycin A. Cells were grown in slow growth medium (PUD) with 0 mM (black), 50 mM (gray), and 100 mM (dotted) concentrations of Validamycin A for 7 days and then counted at time intervals shown. Media was changed every 24 hours to fresh media containing the indicated concentration of drug. -
FIG. 5 shows Pleiotropic Drug Resistance (PDR) genes are up-regulated in metabolically crippled S. cerevisiae cells (rho0). Synchronized rho0 cells (as described inFIG. 1 ) exhibit up-regulated expression (dashed line) of a multi-drug resistance pump (PDRS) as well as genes encoding transcription factors that control pump gene expression (PDR1, PDR3). The expression is compared to synchronized wild type (rho+) cells (solid line). - The present invention now will be described hereinafter with reference to the accompanying drawings and examples, in which embodiments of the invention are shown. This description is not intended to be a detailed catalog of all the different ways in which the invention may be implemented, or all the features that may be added to the instant invention.
- For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. Thus, the invention contemplates that in some embodiments of the invention, any feature or combination of features set forth herein can be excluded or omitted. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant invention. Hence, the following descriptions are intended to illustrate some particular embodiments of the invention, and not to exhaustively specify all permutations, combinations and variations thereof.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
- All publications, patent applications, patents and other references cited herein are incorporated by reference in their entireties for the teachings relevant to the sentence and/or paragraph in which the reference is presented.
- Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination. Moreover, the present invention also contemplates that in some embodiments of the invention, any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a composition comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination.
- As used in the description of the invention and the appended claims, the singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
- Also as used herein, “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).
- The term “about,” as used herein when referring to a measurable value such as a dosage or time period and the like refers to variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified amount.
- As used herein, phrases such as “between X and Y” and “between about X and Y” should be interpreted to include X and Y. As used herein, phrases such as “between about X and Y” mean “between about X and about Y” and phrases such as “from about X to Y” mean “from about X to about Y.”
- The term “comprise,” “comprises” and “comprising” as used herein, specify the presence of the stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
- As used herein, the transitional phrase “consisting essentially of” means that the scope of a claim is to be interpreted to encompass the specified materials or steps recited in the claim and those that do not materially affect the basic and novel characteristic(s) of the claimed invention. Thus, the term “consisting essentially of” when used in a claim of this invention is not intended to be interpreted to be equivalent to “comprising.”
- As used herein, the terms “increase,” “increasing,” “increased,” “enhance,” “enhanced,” “enhancing,” and “enhancement” (and grammatical variations thereof) describe an elevation of at least about 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, 500% or more as compared to a control.
- As used herein, the terms “reduce,” “reduced,” “reducing,” “reduction,” “diminish,” and “decrease” (and grammatical variations thereof), describe, for example, a decrease of at least about 5%, 10%, 15%, 20%, 25%, 35%, 50%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% as compared to a control. In particular embodiments, the reduction can result in no or essentially no (i.e., an insignificant amount, e.g., less than about 10% or even 5%) detectable activity or amount.
- An “antimicrobial molecular target” as used herein means a molecular target (nucleic acid, polypeptide) for an antimicrobial compound.
- As used herein, “infection mimetic conditions” are conditions designed to mimic those found in or on an infected host (e.g., an animal, a plant) such as, for example, conditions of low nutrient, high/low temperature, high/low osmotic potential (high/low salt); high/low humidity, high/low pH, high/low oxygen and that do not support an optimal rate of cell division for any given fungal cell or bacterial cell; that is, conditions that mimic conditions encountered by the organism during infection. Such conditions are well known in the art. Each parameter for an infection mimetic condition is identical to or is within at least about 20% (e.g., about 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%) of the same parameter at a given infection site.
- Infection mimetic conditions are thus suboptimal conditions when compared to the optimal laboratory conditions provided for growth of fungal cells and/or bacterial cells. Infection mimetic conditions include variance in any of the conditions noted above, e.g., variance in temperature as experienced by an organism during daylight/nighttime hours. In some aspects, infection mimetic conditions can be any conditions in which the fungal cell or bacterial cell grows at a lower rate than it grows when placed under standard laboratory conditions that are generally developed to optimize cell growth rate to increase rapidity of experimental/analytical processes. Thus, in some aspects, the infection mimetic conditions provide growth rates for a bacterium or a fungus that are reduced by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or any range or value therein, as compared to growth of the same bacterium or fungus grown under standard laboratory or clinical conditions.
- As used herein, “antiproliferative molecular target” means a molecular target (nucleic acid, polypeptide) for an antiproliferative compound.
- As used herein, “cancer mimetic conditions” means conditions designed to mimic those found at the site of cancer proliferation in a mammal including but not limited to conditions of low nutrient, limited growth factors, high/low temperature, high/low osmotic potential (high/low salt), high/low humidity, high/low pH, high/low oxygen, increased lactate, altered extracellular matrix, and that do not support an optimal rate of cell division for any given mammalian cancer cell; that is, conditions that mimic conditions encountered by the cancer cell during proliferation. Cancer mimetic conditions are thus suboptimal conditions when compared to the optimal laboratory conditions provided for growth of mammalian cancer cells. These conditions are well known in the art and include the tumor microenvironment and/or the intratumoral environment for solid tumors and circulating blood for blood cell cancers. Each parameter for a cancer mimetic condition is identical to or is within at least about 20% (e.g., about 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%) of the same parameter at a given site of cancer proliferation. In some aspects, cancer mimetic conditions can be any conditions in which a cancer cell grows at a lower rate than it grows when placed under standard laboratory conditions that are generally developed to optimize cell growth rate to increase rapidity of experimental/analytical processes. Thus, in some aspects, the cancer mimetic conditions provide growth rates for cancer cells that are reduced by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or any range or value therein, as compared to growth of the same cancer cells grown under standard laboratory or clinical conditions.
- As used herein, “standard laboratory conditions” or “clinical laboratory conditions” are conditions designed to optimize the growth and cell division of an organism or a cancer cell by providing optimal nutrients, temperature, pH, osmotic potential, oxygen, water/humidity; that is, the conditions that provide the optimal rate of cell division and growth for any given fungal cell, bacterial cell or cultured mammalian cancer cell. “Optimized growth conditions” are those used for culture of organisms in a laboratory setting. Conditions are generally developed to optimize cell growth rate to increase rapidity of experimental/analytical processes. While conditions used may not provide the environment for maximal growth rates, they are substantially more favorable than conditions encountered by the cell during growth in the infection mimetic environment
- The present invention is directed in part to novel methods for screening compounds for antimicrobial and antiproliferative activity. The assumption underlying prior known standard screening processes and protocols is that a finding that compounds that fail to exhibit activity against pathogens in these in vitro environments is conclusive as to whether the same molecules will show activity in vivo. The question of whether this assumption is justified or not has rarely been posed, let alone carefully investigated. Although standard approaches based on this assumption have successfully identified a variety of anti-microbial and anti-proliferative drugs, it is clear from our recent research findings that a variety of important drugs and drug targets are missed in primary screens.
- Primary (in vitro) screening protocols are usually optimized to identify drugs or drug targets rapidly and at minimum cost. This generally involves growing organisms in conditions that are optimized for the growth of the pathogen of interest. For example, to screen for antibacterial activity, disease-causing bacteria are grown in a rich medium that supports rapid growth, and then exposed to the potential antibiotic on either solid or liquid media. Cells are then incubated at optimal growth temperatures so that growth-inhibiting properties can be scored rapidly. Protocols of this type have also been standardized for assessing antibiotic sensitivity in clinical settings, so that the proper antibiotic can be used to treat an infection [1]. A further benefit of standardized protocols is the ability to directly compare the relative efficacy of various drugs while holding the environmental conditions constant.
- The central issue facing current standardized screening methods is that the growth conditions are optimized for rapid growth, and these optimized growth conditions are far from what are encountered by pathogenic organisms living in a host. For example, infected tissues do not provide the pathogen with the high levels of sugars (e.g. 2% w/v/dextrose), proteins, and micronutrients available in the rich media formulas used for in vitro growth. Moreover, pathogens are likely to encounter additional stresses such as high temperatures, due to fever, a dynamic osmotic environment, as well as attacks from the immune system. The first indication of the importance of distinguishing between growth conditions in the infected host and in vitro lab test conditions can be seen in the decades of studies and observations indicating that cell growth and division are substantially altered in low nutrient or stressful conditions. This suggests that the response of pathogenic organisms to anti-microbial compounds may be very different when they are grown under optimized growth conditions rather than in nutrient-limited or stressful conditions such as that of infection conditions.
- Several studies demonstrate how fungal cells (S. cerevisiae) respond differently to optimized growth conditions vs. nutrient depleted conditions [2]. Gene expression programs are markedly different when cells are dividing slowly in media depleted for a variety of nutrients. Interestingly, the GRR (Growth Rate Regulated) response (the profile of differentially expressed genes (i.e., up-regulated or down-regulated) is very similar, regardless of which nutrient is depleted [2]. Moreover, the set of GRR genes was found to substantially overlap with a set of ESR (Environmental Stress Response) that are differentially expressed in response to a variety of stresses (e.g. osmotic stress) [3,4]. Genes that exhibited positive correlation with growth rate tended to be genes inhibited by stress, while genes that were down-regulated in fast growth conditions were often activated by stress [2]. As well, considerable overlap was observed between the GRR gene set and the Yeast Metabolic Cycle responsive gene sets identified by Tu et al. [2,5]. Thus, these yeast cells appear to mount a similar gene expression response to either low nutrients (GRR) or a variety of stresses (Stress Response Genes) that is disjoint from the gene expression program observed in cells dividing rapidly in optimized growth conditions.
- Studies that employed a chemostat in which the growth/division rate of cells can be precisely controlled revealed that the gene expression patterns of the GRR are dynamic, and oscillate in a program referred to as the Yeast Metabolic Cycle (YMC). It has been recognized for some time that metabolic processes in yeast are periodically regulated [6] and may be coordinated with the cell cycle [7-9]. When budding yeast cells are grown in continuous culture conditions (chemostat) at appropriate densities and growth rates, the cells synchronize in robust metabolic cycles that can be monitored by periodic changes in dissolved oxygen.
- By sampling continuous cultures of metabolically synchronous populations of budding yeast over time, oscillations in gene expression are identified that are coincident with the periodicity of the YMC. The reported periods of the YMC can vary substantially [4,5,10], and seem to be linked to growth rate [2,4]. The YMC regulates a large transcriptional program and appears to be coordinated with the cell cycle under slow growth conditions. Under continuous culture conditions and a variety of nutritional limitations, researchers demonstrated that all of the GRR transcripts were, in fact, periodic during the YMC [4]. Taken together, these findings suggest that the mechanisms controlling oscillation in transcript abundance are integrating signals from stress, growth rate, YMC and cell cycle.
- The salient question is whether this dynamic program of gene expression in response to nutrient limitation and stress is simply a response to nutrient limitation or stress, or whether its execution is essential for continued growth and division under these slow growth conditions. Those genes that may be important for growth under these conditions of nutrient limitation and stress, once identified may be useful as targets for antimicrobial compounds.
- Accordingly, a first aspect of the invention provides a method of identifying one or more antimicrobial molecular targets in a fungal cell and/or bacterial cell, comprising: growing the fungal cell and/or bacterial cell in vitro under infection mimetic conditions; identifying genes that are differentially expressed (i.e., upregulated or downregulated) in the fungal cell and/or bacterial cell when grown under infection mimetic conditions as compared to the fungal cell and/or bacterial cell grown in vitro under standard or clinical laboratory conditions. In some embodiments, the growth conditions can mimic conditions at a site of an infection by a fungal or bacterial cell (i.e., infection mimetic conditions).
- A second aspect of the invention provides a method of identifying a compound having antimicrobial activity, comprising: growing a microbe (e.g., bacterium or fungus) in vitro under infection mimetic conditions in the presence or absence of a test compound; and selecting a compound that reduces the growth of (e.g., reduces the rate of cell division) or kills the microbe as compared to the microbe grown in vitro under infection mimetic conditions in the absence of the compound.
- A third aspect of the invention provides a method of identifying a compound having antimicrobial activity against a microbe (i.e., bacterium or fungus) in a clinical sample, comprising culturing the clinical sample or a portion of the clinical sample in vitro under conditions that mimic an infection site in the presence or absence of a test compound; selecting a compound that reduces the growth of (e.g., reduces the rate of cell division) or kills the microbe in the clinical sample as compared to the microbe grown in vitro under infection mimetic conditions in the absence of the compound. In some embodiments, the infection site can be where the clinical sample was obtained or the clinical sample can be obtained from a different site. Microbes are bacteria and/or fungi as described herein.
- A clinical sample can be prepared by removing a portion of tissue from a patient/subject and culturing the portion of tissue or other sample on a plate or in a dish in an infection mimetic medium, wherein the growth conditions provided by the infection mimetic media (e.g., temperature, pH, nutrients, etc) mimic those in the infected host organism, for example at the site of infection in the infected organism.
- A clinical sample may be obtained by any method known in the art, such as surgery, biopsy, lavage, aspiration, etc. The sample may be a bodily fluid, e.g., blood, serum, plasma, saliva, urine, cerebrospinal fluid, perspiration, etc.
- As used herein, upregulation of a gene means an increase in expression (i.e., mRNA levels) by that gene of at least about 5% to about 500% or more as compared to a control (e.g., expression levels of the same gene when not grown under infection mimetic or cancer mimetic conditions). Thus, in some embodiments, upregulation of a gene means an increase in mRNA levels of at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 105%, 110%, 115%, 120%, 125%, 130%, 135%, 140%, 145%, 150%, 155%, 160%, 165%, 170%, 175%, 180%, 185%, 190%, 195%, 200%, 205%, 210%, 215%, 220%, 225%, 230%, 235%, 240%, 245%, 250%, 255%, 260%, 265%, 270%, 275%, 280%, 285%, 290%, 295%, 300%, 305%, 310%, 315%, 320%, 325%, 330%, 335%, 340%, 145%, 350%, 355%, 360%, 365%, 370%, 375%, 380%, 385%, 390%, 395%, 400%, 405%, 410%, 415%, 420%, 425%, 430%, 435%, 440%, 445%, 450%, 455%, 460%, 465%, 470%, 475%, 480%, 485%, 490%, 495%, 500%, or any value or range therein. In some embodiments, upregulation of a gene means an increase in mRNA levels of at least about 10% to about 500%, about 10% to about 450%, about 10% to about 400%, about 10% to about 350%, about 10% to about 300%, about 10% to about 250%, about 10% to about 200%, about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 20% to about 500%, about 20% to about 450%, about 20% to about 400%, about 20% to about 350%, about 20% to about 300%, about 20% to about 250%, about 20% to about 200%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 60%, about 30% to about 500%, about 30% to about 450%, about 30% to about 400%, about 30% to about 350%, about 30% to about 300%, about 30% to about 250%, about 30% to about 200%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 60%, about 50% to about 500%, about 50% to about 450%, about 50% to about 400%, about 50% to about 350%, about 50% to about 300%, about 50% to about 250%, about 50% to about 200%, about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 100% to about 500%, about 100% to about 400%, about 100% to about 300%, and the like. The level of upregulation or increase in mRNA expression can vary depending on the organism and/or the particular gene.
- As used herein, down-regulation of a gene means a decrease in expression (i.e., mRNA levels) by that gene of at least about 5% to about 100% compared to a control (e.g., expression levels of the same gene when not grown under infection mimetic or cancer mimetic conditions). Thus, in some embodiments, downregulation of a gene means a decrease in mRNA levels of at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or any value or range therein. In some embodiments, downregulation of a gene means a decrease in mRNA levels of at least about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 15% to about 100%, about 15% to about 90%, about 15% to about 80%, about 15% to about 70%, about 15% to about 60%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 40% to about 100%, about 50% to about 100%, and the like. The level of downregulation or decrease in mRNA expression can vary depending on the organism and/or the particular gene.
- In some embodiments, a compound can reduce the growth or the rate of cell division of the organism by at least about 5% to about 100% as compared to a control. Thus, in some embodiments, the growth or the rate of cell division of an organism can be reduced by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or any value or range therein. In representative embodiments, the rate of growth or the rate of cell division of an organism can be reduced by at least about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 15% to about 100%, about 150% to about 90%, about 15% to about 80%, about 15% to about 70%, about 15% to about 60%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 40% to about 100%, about 50% to about 100%, and the like. The reduction in growth can vary depending on the organism and/or the compound being tested.
- In some embodiments, the site of infection can be in an animal, optionally a mammal, an avian, a reptile, a fish, an amphibian, or an insect. As used herein, a mammal can include but is not limited to a human, non-human primate (e.g., gorilla, monkey, baboon, and chimpanzee, etc.), dog, cat, goat, horse, pig, cow, sheep, and the like, or a laboratory animal (e.g., rats, guinea pigs, mice, gerbils, hamsters, and the like). As used herein, an avian can include but is not limited to a chicken, duck, turkey, goose, quail, pheasant, or a bird kept as a pet (e.g., parakeets, parrots, macaws, cockatoos, canaries, and the like). Both male and female animals and animals of any age are suitable, including embryonic (e.g., in utero or in ovo), infant, juvenile, adolescent, adult and geriatric animals. In representative embodiments, the site of infection can be in a mammal, optionally a human.
- In some embodiments, the site of infection can be in a mammal and the infection mimetic conditions can mimic, for example, cerebral spinal fluid, blood, epidermal surface, mucosal surface (eye, mouth, intestine, genital tract, nasal tract), lung surface, brain tissue, bladder, kidney, a wound, and/or other organ or tissue. These conditions are well known in the art and infection mimetic media can be readily developed to mimic these conditions.
- Exemplary conditions that mimic fungal meningitis infection in cerebral spinal fluid can include normal sodium levels, increased temperature (e.g., fever), low carbohydrate, elevated pH, and low nitrogen and exemplary conditions mimicking a microbial wound site can include low sodium levels, elevated temperature, elevated pH and low nitrogen. Exemplary cancer mimetic mimetic conditions for media of this invention are provided in Table 1.
-
TABLE 1 Exemplary infection mimetic conditions Microbial Fungal Meningitis Microbial Mimetic Blood (Cerebral Spinal Wound Condition Infection Fluid) Infection Salt Content 150 mM NaCl 150 mM NaCl Low NaCl (<150 mM) Temperature >37° C. [18] >37° C. [18] >37° C. [18] Oxygen levels Normoxic Normoxic Hypoxic pH <7.35 ~7.35 [20] 7.15-8.9 [21] Carbohydrate Glucose 5.5 Glucose 3 mMGlucose 5.5 Content mM [23] mM Nitrogen Free Amino Urea 4 mM [23] Free Amino Content Acids [24] Acids [24] Extracellular None None Collagen Matrix Elastin Fibronectin Other cell Macrophages No Macrophages types in co- [25] [25] culture Neutrophils Neutrophils [26] [26] Hormones or Human Serum No Interleukin-1 Cytokines Factors [27] Tumor Necrosis Factor [25] - In some aspects, infection mimetic conditions can be any conditions in which the fungal cell or bacterial cell grows or divides at a lower rate than when placed under standard laboratory conditions that are generally developed to optimize cell growth rate to increase rapidity of experimental/analytical processes. An exemplary medium designed for reduced growth and reduced cell division in a bacterium or a fungus includes, for example, a medium comprising Yeast Nitrogen Base supplemented with essential amino acids and either 3% (v/v) Glycerol/3% (v/v) Ethanol or 3% Ethanol (v/v) only.
- A fungal cell or a bacterial cell can be from any fungal genera or bacterial genera that can cause disease and infection (i.e., pathogenic) in an animal (e.g., in a mammal, an avian, a reptile, a fish, an amphibian, or an insect). Non-limiting examples of bacterial pathogens include Bacillus spp., Bordetella spp., Brucella spp., Borrellia spp., Campylobacter spp., Chlamydia spp., Clostridium spp., Corynebacterium spp., Enteroccocus spp., Escherichia spp., Haemophilus spp., Helicobacter spp., Legionella spp., Leptospira spp., Listeria spp., Mycobacterium spp., Mycoplasma spp., Neisseria spp., Psuedomonas spp., Rickettsia spp., Salmonella spp., Shigella spp., Staphylococcus spp., Streptococcus spp., Vibrio spp., or Yersinia spp. Examples of bacterial species useful with this invention include, but are not limited to, Bacillus anthracis, Bacillus cereus, Bordetella pertussis, Brucella abortus, Brucella canis, Brucella melitensis, Borrelia burgdorferi, Borrelia garinii, Borrelia afzelii, Borrelia recurrentis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheriae, Enteroccocus faecilis, Enteroccocus faecium, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Legionella pneumophila, Leptospira interrogans, Leptospira santarosai, Leptospira weilii, Leptospira noguchii, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Psuedomonas aeruginosa, Rickettsia rickettsia, Salmonella typhi, Salmonella typhimurium, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyrogenes, Vibrio cholerae, or Yersinia pestis, Yersinia enterocolitica or Yersinia pseudotuberculosis. In representative embodiments, the bacterial cell can be a cell from the genera of, for example, Mycobacterium spp., optionally, Mycobacterium tuberculosis.
- Non-limiting examples of an animal fungal pathogen include Cryptococcus spp., Candida spp., Mucor spp., Aspergillus spp., Histoplasma spp, Pneumocytis spp., or Stachybotrys spp. Examples of fungal species useful with this invention include, but are not limited to, Cryptococcus neoformans, Candida albicans, Candida tropicalis, Mucor circinelloides, Aspergillus fumigatus Histoplasma capsulatum, Pneumocytis jirovecii, Trichophyton spp., Epidermophyton spp., Microsporum spp, or Tinea spp. or Stachybotrys chartarum. In representative embodiments, the fungal cell can be a cell from Cryptococcus neoformans, Candida albicans, Candida tropicalis, Mucor circinelloides, and/or Aspergillus fumigatus.
- In representative embodiments, the site of infection can be in a mammal and infection mimetic conditions can mimic cerebral spinal fluid. In some embodiments, a method of identifying one or more antimicrobial molecular targets in a fungal cell or a bacterial cell is provided, comprising: growing the fungal cell or bacterial cell in vitro under infection mimetic conditions that mimic cerebral spinal fluid; identifying genes that are differentially regulated in the fungal cell or bacterial cell when grown under infection mimetic conditions as compared to the fungal cell or bacterial cell grown in vitro under standard or clinical laboratory conditions, wherein the conditions that mimic cerebral spinal fluid comprise a medium comprising phosphate buffered saline (PBS), urea (5 g/L) and 0.1% (w/v) dextrose. In some embodiments, the fungal cell can be Cryptococcus spp., optionally Cryptococcus neoformans. In some embodiments, the standard laboratory conditions that support rapid cell division can comprise a media comprising yeast extract peptone dextrose (YEPD) with 2% (w/v) dextrose.
- In further embodiments, a method of identifying a compound having antimicrobial activity is provided, comprising: growing a fungus or bacterium in vitro under infection mimetic conditions that mimic cerebral spinal fluid in the presence or absence of a test compound; and selecting a compound that reduces the growth of or kills the fungus or bacterium as compared to the fungus or bacterium grown in vitro under infection mimetic conditions in the absence of the compound, wherein the conditions that mimic cerebral spinal fluid comprise a medium comprising phosphate buffered saline (PBS), urea (5 g/L) and 0.1% (w/v) dextrose. In some embodiments, the fungal cell is Cryptococcus spp., optionally Cryptococcus neoformans.
- In still further embodiments, a method of identifying a compound having antimicrobial activity against a fungus or a bacterium in a clinical sample is provided, comprising culturing the clinical sample or a portion of the clinical sample in vitro under conditions that mimic an infection site in the presence or absence of a test compound, wherein the conditions that mimic an infection site mimic cerebral spinal fluid; selecting a compound that reduces the growth of or kills the fungus or a bacterium in the clinical sample as compared to the fungus or a bacterium grown in vitro under infection mimetic conditions in the absence of the compound, wherein the conditions that mimic cerebral spinal fluid can comprise low nitrogen and low carbohydrate. Thus, for example, a condition that mimics cerebral spinal fluid can comprise a medium comprising phosphate buffered saline (PBS), urea (5 g/L) and 0.1% (w/v) dextrose. In some embodiments, the fungal cell can be Cryptococcus spp., optionally Cryptococcus neoformans. In some embodiments, the infection site can be where the clinical sample was obtained or the clinical sample can be obtained from a different site. Exemplary optimal growth media for budding yeast and other microbes can include, but is not limited to, (1) YEP medium comprising 10 g yeast extract, 10 g Bacto peptone, 5 g NaCl in a total volume of 1 L of water, pH to 7.0) and 2% (w/v) dextrose; (2) yeast nitrogen base (YNB) medium supplemented with essential amino acids, 2% (w/v) dextrose and either: (i) 3% glycerol/3% ethanol (v/v) or (ii) 3% ethanol (v/v); (3) yeast extract peptone dextrose (YEPD) medium comprising yeast extract peptone dextrose and 2% (w/v) dextrose.
- In further embodiments, the site of infection can be in or on a plant and the infection mimetic conditions can mimic conditions on a plant surface (leaf, stem, flower, root, fruit), in phloem, in xylem, or within and/or between a plant's cells (i.e., intracellular and/or intercellular), and/or in or on other plant tissue types. In still further embodiments, the site of infection can be in or on a plant and the infection mimetic conditions can mimic conditions in the soil. The conditions on a plant surface (e.g., leaf surface, stem surface, petal surface, and the like) at the time of bacterial or fungal infection can be the conditions at the site of infection that are mimicked as disclosed herein. As the ordinary skilled person understands, these conditions can vary based on the plant species as well as where the plant is located (that is, the environment in which the plant is growing—e.g., macroenvironment). The environment around the plant will have an impact on the choice of conditions to be mimicked. Thus, a plant can be growing, for example, under a high humidity to low humidity conditions, high heat to low heat conditions, high light to low light conditions, or conditions of drought to flood conditions, and the like. These factors not only affect the plant but their environment experienced by plant pathogens. A further consideration is the plant microenvironment, which constitutes the environment of a small group of plants down to the environment experienced by a single plant. The conditions that a fungal pathogen or a bacterial pathogen may experience on the surface of a plant can be a combination of the effects of microenvironment and the macroenvironment. For example, a bacterial pathogen or a fungal on the surface of plant and prior to entry into the plant will likely find conditions of low nutrient availability (e.g., low nitrogen and/or low carbohydrate levels) on the plant surface. The humidity may be low due to dry surrounding conditions. These and other factors are taken into account when developing media for mimicking infections conditions for microbes on plant surfaces.
- In some embodiments, the plant can include, but is not limited to, an angiosperm, a gymnosperm, a bryophyte, a fern and/or fern ally. In some embodiments, the plant can be a cell, plant and/or plant part of any plant species. Non-limiting examples of plants useful with the methods of the present invention include turf grasses, vegetable crops, including artichokes, kohlrabi, arugula, leeks, asparagus, lettuce (e.g., head, leaf, romaine), malanga, melons (e.g., muskmelon, watermelon, crenshaw, honeydew, cantaloupe), cole crops (e.g., brussels sprouts, cabbage, cauliflower, broccoli, collards, kale, chinese cabbage, bok choy), cardoni, carrots, napa, okra, onions, celery, parsley, chick peas, parsnips, chicory, peppers, potatoes, cucurbits (e.g., marrow, cucumber, zucchini, squash, pumpkin), radishes, dry bulb onions, rutabaga, eggplant, salsify, escarole, shallots, endive, garlic, spinach, green onions, squash, greens, beet (sugar beet, fodder beet), sweet potatoes, swiss chard, horseradish, tomatoes, turnips, and spices; a fruit and/or vine crop such as apples, apricots, cherries, nectarines, peaches, pears, plums, prunes, cherry, quince, almonds, chestnuts, filberts, pecans, pistachios, walnuts, citrus, blueberries, boysenberries, cranberries, currants, loganberries, raspberries, strawberries, blackberries, grapes, avocados, bananas, kiwi, persimmons, pomegranate, pineapple, tropical fruits, pomes, melon, mango, papaya, and lychee, a field crop plant such as clover, alfalfa, evening primrose, meadow foam, corn/maize (field, sweet, popcorn), hops, jojoba, peanuts, rice, safflower, small grains (barley, oats, rye, wheat, etc.), sorghum, tobacco, kapok, a leguminous plant (beans, lentils, peas, soybeans), an oil plant (rape, mustard, poppy, olive, sunflower, coconut, castor oil plant, cocoa bean, groundnut), Arabidopsis, a fiber plant (cotton, flax, hemp, jute), lauraceae (cinnamon, camphor), or a plant such as coffee, sugar cane, tea, and natural rubber plants; and/or a bedding plant such as a flowering plant, a cactus, a succulent and/or an ornamental plant, as well as trees such as forest (broad-leaved trees and evergreens, such as conifers), fruit, ornamental, and nut-bearing trees, as well as shrubs and/or other nursery stock.
- In some embodiments, a fungal cell or a bacterial cell can be from any fungal genera or bacterial genera that can cause disease and infection (i.e., is pathogenic) in a plant. Non-limiting examples of fungal plant pathogens include Alternaria spp., Aspergillus spp., Botryodiplodia spp., Botrytis spp., Cercospora spp., Cladosporium spp., Clavoceps spp., Cochliobolus spp., Colletotrichum spp., Diaporthe spp., Diplodia spp., Drechslera spp., Erysiphe spp., Fusarium spp., Gibberella spp., Glomerella spp., Helminthosporium spp., Leptosphaeria spp., Leucostoma spp., Magnaporthe spp., Mucor spp., Mycosphaerella spp., Nectria spp., Oidium spp., Phoma spp., Phyllosticta spp., Pleospora spp., Podosphaera spp., Puccinia spp., Ramularia spp., Rhizoctonia spp., Schizophyllum spp., Sclerotinia spp., Sclerotium spp., Septoria spp., Thielaviolsis spp., Tilletia spp., Uromyces spp., Ustilago spp., or Verticillium spp. Examples of plant pathogenic fungal species useful with this invention include, but are not limited to, Alternaria brassicola, Alternaria dianthi, Alternaria alternata, Alternaria raphani, Aspergillus niger, Botryodiplodia umicola, Botryodiplodia ocidii, Botrytis cinerea, Botrytis fabae, Botrytis narcissicola, Cercospora apii, Cercospora beticola, Cercospora kikuchii, Cladosporium arthropodii, Cladosporium cladosporoides, Clavoceps purpurea, Cochliobolus carbonum, Cochliobolus sativus, Colletotrichum glycines, Colletotrichum orbiculare, Colletotrichum pisi, Colletotrichum trifoli, Diaporthe helianthi, Diaporthe perniciosa, Diaporthe phaeolorum, Diplodia seriata, Drechslera avenacea, Erysiphe graminis, Fusarium solani, Fusarium graminearum, Fusarium oxysporum, Fusarium pallidoroseum, Fusarium sacchari, Gibberella avenacea, Gibberella acuminata, Gibberella fujikuroi, Gibberella zeae, Glomerella cingulata, Helminthosporium cookei, Helminthosporium solani, Leptosphaeria acuta, Leptosphaeria maculans, Leptosphaeria sacchari, Leucostoma auerswaldii, Leucostoma kunzei, Magnaporthe grisea, Mucor circinelloides, Mucor hiemalis, Mucor piriformis, Mucor citricolor, Mycosphaerella terrestris, Mycosphaerella brassicicola, Mycosphaerella dendroides, Mycosphaerella graminicola, Mycosphaerella polymorpha, Mycosphaerella pyri, Nectria cinnabarina, Nectria radicicola, Oidium indicum, Oidium mangiferae, Phoma nebulosa, Phoma microspora, Phoma sclerotioides, Phyllosticta batatas, Phyllosticta carpogena, Phyllosticta nicotianae, Phyllosticta perseae, Pleospora herbarum, Pleospora lycopersici, Pleospora thea, Podosphaera leucotricha, Puccinia aristidae, Puccinia coronata, Puccinia erianthi, Puccinia hordei, Puccinia malvacearum, Puccinia purpurea, Puccinia xanthii, Ramularia menthicola, Rhizoctonia leguminicola, Rhizoctonia solani, Rhizoctonia solani, Schizophyllum commune, Sclerotinia borealis, Sclerotinia minor, Sclerotinia spermophila, Sclerotium cinnomomi, Sclerotium spermophila, Septoria bataticola, Septoria glycines, Septoria helianthi, Septoria pisi, Thielaviolsis basicola, Tilletia tritici, Uromyces beticola, Uromyces graminis, Uromyces pisi-sativi, Uromyces musae, Ustilago hordei, Ustilago esculenta, Ustilago maydis, Ustilago tritici, Verticillium albo-atrum, Verticillium dahliae, Verticillium alfalfae, Verticillium longisporum, or Verticillium theobromae.
- Non-limiting examples of bacterial plant pathogens include Acetobacter spp., Agrobacterium spp., Arthrobacter spp., Bacillus spp., Clavibacter spp., Clostridium spp., Corynebacterium spp., Erwinia spp., Nocardia spp., Pseudomonas spp., Serratia spp., Streptomyces spp., Xanthomonas spp., or Xylella spp. Examples of species of plant pathogenic bacteria useful with this invention include, but are not limited to, Acetobacter aceti, Acetobacter pasteurianus, Agrobacterium radiobacter, Agrobacterium rhizogenes, Agrobacterium rubi, Agrobacterium tumefaciens, Arthrobacter ilicis, Bacillus megaterium, Bacillus pumilus, Clavibacter iranicus, Clavibacter rathayi, Clavibacter tritici, Clavibacter xyli, Clostridium puniceum, Corynebacterium beticola, Corynebacterium flaccumfaciens, Corynebacterium michiganensis, Erwinia chrysanthemi, Erwinia paradisiaca, Erwinia cancerogena, Erwinia dissolvens, Erwinia carotovora, Erwinia herbicola, Erwinia pyrofoliae, Erwinia rhapontici, Erwinia stewartii, Nocardia vaccinii, Pseudomonas agarici, Pseudomonas amygdali., Pseudomonas avenae, Pseudomonas corrugata, Pseudomonas gladioli, Pseudomonas marginalis, Pseudomonas savastanoi, Pseudomonas syringae, Pseudomonas savastanoi, Serratia proteamaculans, Streptomyces acidiscabies, Streptomyces candidus, Streptomyces intermedius, Streptomyces reticuliscabei, Xanthomonas arboricola, Xanthomonas alfalfae, Xanthomonas campestris, Xanthomonas citri, or Xylella fastidiosa.
- Additionally provided are media that mimic conditions at an infection site in an organism. For example, when the organism is an animal, optionally a mammal, the media that mimic conditions at an infection site can mimic conditions of cerebral spinal fluid, blood, epidermal surface, mucosal surface (eye, mouth, intestine, genital tract, nasal tract), lung surface, brain tissue, bladder, kidney, wound, or other organ or tissue, and the conditions can mimic cerebral spinal fluid, blood, epidermal surface, mucosal surface (eye, mouth, intestine, genital tract, nasal tract), lung surface, brain tissue, bladder, kidney, a wound, and/or other organ or tissue. In particular embodiments, the invention provides media that mimics cerebral spinal fluid comprising low nitrogen and low carbohydrate (e.g., low glucose). In further embodiments, when the organism is a plant, the media that mimic conditions at an infection site can mimic conditions on a plant surface (leaf, stem, flower, root, fruit), in phloem, in xylem, or within and/or between a plant's cells (i.e., intracellular and/or intercellular), and/or in or on other plant tissue types. In still further embodiments, the media that mimic conditions at an infection site can mimic conditions in the soil.
- The invention further provides a method of treating a fungal infection in an organism, comprising administering to an organism in need thereof a therapeutically effective amount of validamycin A. In some embodiments, the organism can be an animal and the fungal infection can be caused by Cryptococcus spp., Candida spp., Mucor spp., and/or Apergillus spp, optionally the fungal infection can be caused by Cryptococcus neoformans, Candida albicans, Candida tropicalis, Mucor circinelloides, and/or Aspergillus fumigatus. In some embodiments, the organism can be a plant and the fungal infection is not caused by Rhizoctonia spp., optionally not by Rhizoctonia solani. In representative embodiments, the plant is not rice and the fungal infection is not caused by Rhizoctonia spp., optionally not by Rhizoctonia solani.
- An additional aspect of the invention provides a method of identifying one or more antiproliferative molecular targets in a mammalian cancer cell, comprising: growing the mammalian cancer cell in vitro under cancer mimetic conditions; identifying genes that are upregulated in the mammalian cancer cell when grown under cancer mimetic conditions as compared to the mammalian cancer cell grown in vitro under standard or clinical laboratory conditions.
- A further aspect of the invention provides a method of identifying a compound having antiproliferative activity, comprising: growing a mammalian cancer cell in vitro under cancer mimetic conditions in the presence or absence of a test compound; and selecting a compound that reduces the growth of (e.g., reduce the rate of cell division) or kills the mammalian cancer cell as compared to the mammalian cancer cell grown in vitro under cancer mimetic conditions in the absence of the compound.
- A still further aspect of the invention provides a method of identifying a compound having antiproliferative activity against a mammalian cancer cell in a clinical sample, comprising culturing the clinical sample or a portion of the clinical sample in vitro under conditions that mimic a site of cancer proliferation in the presence or absence of a test compound; and selecting a compound that reduces the growth of (e.g., reduce the rate of cell division) or kills the mammalian cancer cell in the clinical sample as compared to the mammalian cancer cell grown in vitro under cancer mimetic conditions in the absence of the compound.
- A clinical sample can be prepared by removing a portion of tissue from a patient/subject and culturing the portion of tissue on a plate or in a dish in a cancer mimetic medium, wherein the growth conditions provided by the cancer mimetic media (e.g., temperature, pH, nutrients, etc) mimic those in the organism, for example at the site of cancer proliferation in the organism.
- An exemplary mammalian cancer cell includes a carcinoma cell, sarcoma cell, lymphoma cell, leukemia cell, or germinoma cell. In other embodiments, the mammalian cancer cell includes, but is not limited to, a pancreatic cancer cell, liver cancer cell, colon cancer cell, breast cancer cell, cervical cancer cell, vaginal cancer cell, testicular cancer cell, skin cancer cell, prostate cancer cell, mouth cancer cell, bone cancer cell, esophageal cancer cell, lymphoma cell, leukemia cell, lung cancer cell, colon cancer cell, rectal cancer cell, kidney cancer cell, brain cancer cell, and gastric cancer cell.
- In some embodiments, the growth conditions for the mammalian cancer cell mimic conditions at a site of cancer proliferation (i.e., cancer mimetic conditions). In some embodiments, the site of cancer proliferation can be, but is not limited to, blood, pancreas, liver, colon, breast, cervix, vagina, testicle, skin, prostate, lymph node, lung, rectum, esophagus, mouth, bone, colon, kidney, brain, stomach, a wound and/or other organ or tissue.
- In representative embodiments, the clinical sample can be obtained from the site of cancer proliferation or it can be obtained from another site in/on the organism. In some embodiments, the growth conditions for the mammalian cancer cell mimic conditions at, for example, the site of solid tumors and/or leukemias/lymphomas in blood, pancreas, liver, colon, breast, cervix, vagina, testicle, skin, prostate, lymph node, lung, rectum, esophagus, mouth, bone, colon, kidney, brain, stomach, a wound, and/or other organ or tissue.
- In some embodiments, the site of cancer proliferation can be the stomach, wherein the cancer cell is a stomach cancer cell, and the cancer mimetic conditions comprise a media comprising high pH, Heliobacter pylori infection, low oxygen, and restricted nutrients. The invention further provides a cancer mimetic media that mimics conditions at a site of cancer growth in a mammal.
- In some embodiments, a cancer mimetic condition for a solid tumor can include, for example, low sodium, low oxygen (e.g., hypoxic), low carbohydrate, and low available nitrogen. A cancer mimetic condition for a blood cancer, lymphoma or leukemia can include, for example, normal sodium levels, increased temperature (e.g., fever), low carbohydrate, elevated pH, and low nitrogen. See, Table 1 for exemplary infection mimetic conditions for media of this invention.
-
TABLE 2 Exemplary cancer mimetic conditions Mimetic Blood Cancer Condition Solid Tumor Lymphoma or Leukemia Salt Content Low NaCl (<135 mM) 150 mM NaCl [16] Temperature 37° C. >37° C. [17] Oxygen levels Hypoxic Normoxic pH ~7.0 [19] ~7.35 Carbohydrate Lactate 6-10 μM/g [22] Glucose 5.5 mM Content Glucose 5.5 mM Nitrogen Free Amino Acids Free Amino Acids [24] Content [24] Extracellular Matrix None Matrix Metaloproteases Collagen Fibronectin Other cell Cancer Stem Cells No types in co- Normal Mesenchymal culture Cells Hormones or Tumor Dependent No Cytokines - The invention will now be described with reference to the following examples. It should be appreciated that these examples are not intended to limit the scope of the claims to the invention, but are rather intended to be exemplary of certain embodiments. Any variations in the exemplified methods that occur to the skilled artisan are intended to fall within the scope of the invention.
- Several studies demonstrate how fungal cells (S. cerevisiae) respond differently to optimized growth conditions vs. nutrient depleted conditions. Gene expression programs are markedly different when cells are dividing slowly in media depleted for a variety of nutrients. Interestingly, the GRR (Growth Rate Regulated) response (the profile of up-regulated and down-regulated genes) is very similar, regardless of which nutrient is depleted. Moreover, the set of GRR genes was found to substantially overlap with a set of genes (Environmental Stress Response; ESR) that are up- or down-regulated in response to a variety of stresses (e.g. osmotic stress). Genes that exhibited positive correlation with growth rate tended to be genes inhibited by stress, while genes that were down-regulated in fast growth conditions were often activated by stress. As well, there was considerable overlap between the GRR gene set and the YMC responsive gene sets. Thus, these yeast cells appear to mount a similar gene expression response to either low nutrients (GRR) or a variety of stresses (Stress Response Genes) that is disjoint from the gene expression program observed in cells dividing rapidly in optimized growth conditions.
- Studies that employed a chemostat in which the growth/division rate of cells can be precisely controlled revealed that the gene expression patterns of the GRR are dynamic, and oscillate in a program referred to as the Yeast Metabolic Cycle (YMC). It has been recognized or some time that metabolic processes in yeast are periodically regulated and may be coordinated with the cell cycle. When budding yeast cells are grown in continuous culture conditions (chemostat) at appropriate densities and growth rates, the cells synchronize in robust metabolic cycles that can be monitored by periodic changes in dissolved oxygen.
- By sampling continuous cultures of metabolically synchronous populations of budding yeast over time, investigators have identified oscillations in gene expression that are coincident with the periodicity of the yeast metabolic cycle (YMC). The reported periods of the YMC can vary substantially, and seem to be linked to growth rate. The YMC regulates a large transcriptional program and appears to be coordinated with the cell cycle under slow growth conditions. In a recent study using continuous culture conditions and a variety of nutritional limitations, researchers demonstrated that all of the GRR transcripts were, in fact, periodic during the YMC. Taken together, these findings suggest that the mechanisms controlling oscillation in transcript abundance are integrating signals from stress, growth rate, YMC and cell cycle.
- The salient question is whether this dynamic program of gene expression in response to nutrient limitation and stress is simply a response to nutrient limitation or stress, or whether its execution is essential for continued growth and division under these slow growth conditions.
- In studies aimed at understanding how metabolic mutations that alter growth rates regulate the cell division clock, rho0 mutants were used that lack mitochrondrial DNA, and thus, are forced to ferment sugar sources rather than do oxidative phosphorylation. These mutant cells are metabolically perturbed and grow slowly (primarily in G1). By performing time series transcriptomic experiments in a cell-cycle synchronized time series experiment in batch culture, we found that these cells were going through both cell cycle oscillations and metabolic oscillations (YMC). This is an exciting finding, as the integration of the two cycles has been difficult to interrogate in chemostat culture systems.
- Two distinct and coupled cycling programs of gene expression were identified in cells growing in rho0 mutant cells that were growing slowly. Using algorithms to identify periodic behaviors, we identified two distinct sets of oscillatory programs. These two programs are depicted in
FIG. 1 . The cell cycle oscillation depicted on the lower left is common to cells growing in optimized or nutrient non-limiting conditions. The metabolic oscillations on the lower right are found only in metabolic mutants or in cells in limiting nutrient conditions. - Within the metabolic oscillation program, we discovered that genes for an entire metabolic pathway (trehalose storage and utilization) were expressed periodically at very high levels in the rho0 mutants, but were not observed to be elevated in normal cells (
FIG. 2 ). A variety of sources suggest a model in which cells growing under metabolically stressful conditions store and burn trehalose in order to continue cycling [6,11]. Thus, the trehalose pathway may be one important connection between the cell cycle clock and the YMC, and may be a pathway that is essential for cell division in metabolic mutants or in nutrient-limited media. - To test whether genes of the trehalose pathway might be essential for growth in nutrient-limiting conditions, we made knockout mutants in several genes of the trehalose pathway including TPS1, TPS2 (trehalose synthases) as well as NTH1 (trehalase). We then monitored growth in nutrient limiting media (Glycerol or Glycerol/Ethanol). As shown in
FIG. 3 , deletion of the trehalose pathway genes did not impair growth in optimal growth medium (YEP+2% (w/v) dextrose) but three out of four of the mutations (tps2, ath1, nth1) severely inhibited growth in nutrient-limiting medium (SC-Ethanol). Furthermore, we could not knock out these genes in rho0 cells, suggesting they are required for growth of metabolically disabled mutants. - These genetic knockout experiments support the hypothesis that at least some genes expressed differentially in nutrient-depleted conditions (as compared to optimized growth conditions) may be required for growth in the nutrient-depleted conditions. If these nutrient-depleted, slow growth conditions mimic the slow growth, stressful conditions encountered by pathogens in an in vivo infection, then it is likely that there is an array of potential drug targets that would have been missed during screens in optimized growth conditions. Strikingly, tps1 tps2 A knockout mutants in the fungal pathogen, Cryptococcus neoformans, have been shown to be essentially avirulent in a rabbit meningitis model system [12]. Since the current thinking in the field is that the role of trehalose in virulence is related to the osmotic stabilization of proteins, rather than being an essential fuel source when cells are growing in nutrient-depleted conditions, the potential relevance of this fact has been missed.
- While optimizing screening protocols for speed and low cost has obvious benefits both in research and clinical settings, screening conditions that are optimized for speed and cost often bear little resemblance (if any) to the conditions encountered by cells during the infection of a human host. For example, during an infection, C. neoformans yeast cells grow and divide in the cerebral spinal fluid (CSF) of infected patients. CSF is low in glucose and nitrogen, and during infection, the host temperature is elevated, leading to slow division of the yeast cells [13]. By contrast, the standardized primary in vitro screening conditions (i.e., standard laboratory conditions) are much higher in glucose and nitrogen, and cells are grown at lower temperatures to stimulate rapid growth. Thus, the growth conditions encountered by the yeast cells during infection are very different than those encountered in standardized screening protocols.
- The inventors have discovered that the transcriptional activation or repression of some fraction of the genes controlling the cell cycle is important for cell division in the face of limiting nutrients or stress, that is, the activation or repression of this fraction of genes is important when the organism enters in the slow growth mode. Furthermore, most of the conditions likely to be encountered by microbes attempting to divide in a host during an infection scenario are sub-optimal and force cells to divide slowly. The same appears to be true for tumor cells growing in a solid tumor lacking an adequate blood supply. Genes in pathways important for division in sub-optimal growth conditions represent viable drug targets for anti-microbial or anti-proliferative compounds targeted at the organisms whose slow growth programs involve expression of these genes.
- Here, we determined whether a trehalose-mimetic compound (Validamycin A) produced by a Streptomyces bacterium, could target the trehalose pathway in S. cerevisiae and in C. neoformans, and inhibit their cell division in sub-optimal growth conditions. Validamycin A had no effect on division rates in optimal growth conditions (YEPD+2% (w/v) Dextrose), but severely inhibited division rates in slow growth conditions (PUD medium; PBS, 5g/L Urea, supplemented with 0.1% (w/v) dextrose was used, which mimics nutrient conditions in cerebral spinal fluid) (
FIG. 4 ). Plating assays indicate that Validamycin A is fungicidal in these conditions, as colony forming units are substantially reduced when cells are exposed to Validamycin A under slow growth conditions. - Mutants in the trehalose pathway do not exhibit the rapid division phenotype in optimal growth conditions, suggesting that SFG1 functions in a distinct genetic pathway that normally restrains division in sub-optimal growth conditions. Based on our collection of gene expression data and genetic knockout experiments, we predict that there are multiple genes and pathways that are essential for slow division in sub-optimal growth conditions. We expect these pathways to be involved in, for example: (1) the metabolism of storage carbohydrates that accumulate in nutrient depleted growth media. (e.g., genes involved in trehalose storage, transport, and metabolism including: TPS2, NTH1, NTH2); (2) the prevention of cell-cycle entry until sufficient nutrients and energy have been stored. (e.g., genes such as SFG1); and (3) the protection of cellular components from stresses induced by metabolic pathways specific to slow growth (including oxidative and osmotic stresses) (e.g., genes such as HOG1 and SLT2, and Rad53).
- When mutated, the gene encoding Sfgl has a phenotype similar (but not identical) to the trehalose pathways. Mutant cells where the Sfg1 gene has been deleted (sfglΔ) exhibit a more rapid division rate than wild-type cells in optimal growth conditions, but are severely impaired for division in sub-optimal growth conditions. These findings suggest that SFG1 may play a role in restraining entry into the cell division cycle in response to slow growth conditions.
- We have every reason to believe our discoveries in S. cerevisiae and C. neoformans will be applicable to other important fungal pathogens, including but not limited to, Candida albicans, Candida tropicalis, Mucor species such as Mucor circinelloides, and Aspergillus fumigatus.
- Previous studies have investigated the efficacy of Validamycin A in preventing the growth of Candida albicans [14] and concluded that Validamycin A is not effective as an antifungal agent against C. albicans. These experiments were performed in rich medium and fit with our discovery that screening conditions are likely important in determining in vitro and in vivo efficacy of anti-fungal agents.
- Trehalose has been shown to be an important molecule for the growth and virulence of pathogenic bacteria in the genus Mycobacteria, including Mycobacterium tuberculosis. Mycobacteria in general are extremely slow growing and often refractory to antibiotic treatments. It is not clear whether trehalose pathways are part of a slow-division pathway in Mycobacteria, but these findings suggest that genetic pathways essential for slow division may exist in bacterial species in addition to fungi. Thus, the application of our infection mimetic growth conditions to bacterial species may yield new insights into novel antibiotic targets [28].
- Screening clinical isolates for drug sensitivity is an important aspect of a clinical treatment protocol. Growth conditions for clinical screening are very specific [15] and utilize growth-optimized conditions that likely do not reflect in vivo conditions in the infected patient. Our experiments have revealed that several genes encoding multidrug resistance-like pumps are up-regulated when fungal cells are exposed to slow-growth conditions (see, FIG.
- 5). Here, Pleiotropic Drug Resistance (PDR) genes are up-regulated in metabolically crippled S. cerevisiae cells(rho0). Synchronized rho0 cells (as described in
FIG. 1 ) exhibit up-regulated expression (dashed line) of a multi-drug resistance pump (PDRS) as well as genes encoding transcription factors that control pump gene expression (PDR1, PDR3). Thus, it is expected that the up-regulation of these pumps could contribute to drug resistance in vivo, but not in growth-optimized conditions (i.e., standard laboratory conditions). Thus, conditions used for clinical screening for drug sensitivity/resistance may be further optimized by an additional screening step performed in infection mimetic conditions as described herein. - The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.
-
- 1. Fothergill, A. W., Rinaldi, M. G., and Sutton, D. A. (2006). Antifungal susceptibility testing. Infectious disease clinics of North America 20, 699-709.
- 2. Brauer, M. J., Huttenhower, C., Airoldi, E. M., Rosenstein, R., Matese, J. C., Gresham, D., Boer, V. M., Troyanskaya, O. G., and Botstein, D. (2008) Coordination of growth rate, cell cycle, stress response, and metabolic activity in yeast. Mol Biol Cell 19, 352-367.
- 3. Gasch, A. P., Spellman, P. T., Kao, C. M., Carmel-Harel, O., Eisen, M. B., Storz, G., Botstein, D., and Brown, P. O. (2000). Genomic expression programs in the response of yeast cells to environmental changes. Mol Biol Cell 11, 4241-4257.
- 4. Slavov, N., and Botstein, D. (2011). Coupling among growth rate response, metabolic cycle, and cell division cycle in yeast. Mol Biol Cell 22, 1997-2009.
- 5. Tu, B. P., Kudlicki, A., Rowicka, M., and McKnight, S. L. (2005). Logic of the yeast metabolic cycle: temporal compartmentalization of cellular processes. Science 310, 1152-1158.
- 6. Futcher, B. (2006). Metabolic cycle, cell cycle, and the finishing kick to start.
Genome Biol 7, 107. - 7. Creanor, J. (1978). Carbon dioxide evolution during the cell cycle of the fission yeast Schizosaccharomyces pombe. J Cell Sci 33, 385-397.
- 8. Novak, B., and Mitchison, J. M. (1986). Change in the rate of CO2 production in synchronous cultures of the fission yeast Schizosaccharomyces pombe: a periodic cell cycle event that persists after the DNA-division cycle has been blocked. J Cell Sci 86, 191-206.
- 9. Novak, B., and Mitchison, J. M. (1990). Changes in the rate of oxygen consumption in synchronous cultures of the fission yeast Schizosaccharomyces pombe. J Cell Sci 96 (Pt 3), 429-433.
- 10. Klevecz, R. R., Bolen, J., Forrest, G., and Murray, D. B. (2004). A genomewide oscillation in transcription gates DNA replication and cell cycle. Proc Natl Acad Sci USA 101, 1200-1205.
- 11. Haase, S. B., and Wittenberg, C. (2014). Topology and control of the cell-cycle-regulated transcriptional circuitry. Genetics 196, 65-90.
- 12. Petzold, E. W., Himmelreich, U., Mylonakis, E., Rude, T., Toffaletti, D., Cox, G. M., Miller, J. L., and Perfect, J. R. (2006). Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. Infection and immunity 74, 5877-5887.
- 13. Mandal, R., Guo, A. C., Chaudhary, K. K., Liu, P., Yallou, F. S., Dong, E., Aziat, F., and Wishart, D. S. (2012). Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update.
Genome medicine 4, 38. - 14. Guirao-Abad, J. P., Sanchez-Fresneda, R., Valentin, E., Martinez-Esparza, M., and Arguelles, J. C. (2013). Analysis of validamycin as a potential antifungal compound against Candida albicans. Intl Microbiol 16, 217-225.
- 15. Cuenca-Estrella, M., Gomez-Lopez, A., Alastruey-Izquierdo, A., Bernal-Martinez, L., Cuesta, I., Buitrago, M. J., and Rodriguez-Tudela, J. L. (2010). J Clin. Microbiol. 48, 1782-1786.
- 16. Onitilo A A, Kio E, Doi SAR: Clinical Medicine & Research 2007, 5:228-237.
- 17. Peng L H, Keng T C, Sinniah D: Cancer 1981, 47:583-587.
- 18. Luft F C, Rissing J P, White A, Brooks GF: Am J Med Sci 1976, 272:65-74.
- 19. Tannock I F, Rotin D: Cancer Res 1989, 49:4373-4384.
- 20. Merril C R, Seipp H W, Luchsinger PC: J Appl Physiol 1961, 16:485-487.
- 21. Gethin G: Wounds uk 2007, 3:52.
- 22. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad E K, Mueller-Klieser W: Cancer Research 2000, 60:916-921.
- 23. Mandal R, Guo AC, Chaudhary K K, Liu P, Yallou F S, Dong E, Aziat F, Wishart D S: Genome Medicine 2012, 4:1-11.
- 24. Canepa A, Divino Filho J C, Gutierrez A, Carrea A, Forsberg A M, Nilsson E, Verrina E, Perfumo F, Bergstrom J: Nephrology Dialysis Transplantation 2002, 17:413-421.
- 25. Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C: Journal of Leukocyte Biology 1994, 55:410-422.
- 26. Rubin-Bejerano I, Abeijon C, Magnelli P, Grisafi P, Fink G R: Cell host & microbe 2007, 2:55-67.
- 27. Madhani H D, Fink G R: Trends Cell Biol 1998, 8:348-353.
- 28. Nobre, A., Alarico, S., Maranha, A., Mendes, V., and Empadinhas, N. (2014). Microbiology. 160(Pt8), 1547-70.
Claims (16)
1-48. (canceled)
49. A method of identifying a compound having antimicrobial activity against budding yeast cells, comprising:
(a) growing the budding yeast cells in vitro under infection mimetic conditions to produce a metabolically synchronous population of budding yeast cells;
(b) adding a test compound to the metabolically synchronous population of budding yeast cells;
(c) identifying reduced growth or killing of the budding yeast cells in the presence of the test compound; and
(d) identifying the compound having antimicrobial activity against budding yeast cells under infection mimetic conditions.
50. The method of claim 49 , wherein the infection mimetic conditions mimic blood of the infected animal and comprise growing the budding yeast cell in a growth media comprising 150 mM NaCl, 5.5 mM glucose, free amino acids, macrophages, neutrophils, and human serum factors at a temperature of greater than 37° C. and a pH of <7.35 with normoxic oxygen levels.
51. The method of claim 49 , wherein the infection mimetic conditions mimic a wound infection in the animal and comprise growing the budding yeast cell in a media comprising less than 150 mM NaCl, 5.5 mM glucose, free amino acids, collagen, elastin, fibronectin macrophages, neutrophils, interleukin, and tumor necrosis factor at a temperature of greater than 37° C. and a pH ranging from 7.15 to 8.9 with hypoxic oxygen levels.
52. The method of claim 49 , wherein the infection mimetic conditions mimic cerebral spinal fluid of the infected animal and comprise growing the budding yeast cell in a media comprising phosphate buffered saline (PBS), 5 g/L of urea and 0.1% dextrose or in a media comprising 150 mM NaCl, 3 mM glucose, and 4 mM urea at a temperature of greater than 37° C. and a pH of about 7.35 with normoxic oxygen levels.
53. The method of claim 49 , wherein the budding yeast cell is a Cryptococcus spp., Candida spp., or Mucor spp.
54. A method of identifying a modification in a gene expression pattern in a budding yeast cell comprising:
(a) growing the budding yeast cell in vitro under infection mimetic conditions to produce a metabolically synchronous population of budding yeast cells;
(b) sampling continuous cultures of such metabolically synchronous population of cells over time; and
(c) identifying one or more genes that are differentially expressed when the budding yeast cells are grown in vitro under infection mimetic conditions as compared to when grown under standard laboratory conditions, thereby identifying a modification in a gene expression pattern during growth of budding yeast cells under infection mimetic conditions.
55. The method of claim 54 wherein the infection mimetic conditions mimic blood of the infected animal and comprise growing the budding yeast cell in a growth media comprising 150 mM NaCl, 5.5 mM glucose, free amino acids, macrophages, neutrophils, and human serum factors at a temperature of greater than 37° C. and a pH of <7.35 with normoxic oxygen levels.
56. The method of claim 54 , wherein the infection mimetic conditions mimic a wound infection in the animal and comprise growing the budding yeast cell in a media comprising less than 150 mM NaCl, 5.5 mM glucose, free amino acids, collagen, elastin, fibronectin macrophages, neutrophils, interleukin, and tumor necrosis factor at a temperature of greater than 37° C. and a pH ranging from 7.15 to 8.9 with hypoxic oxygen levels.
57. The method of claim 54 , wherein the infection mimetic conditions mimic cerebral spinal fluid of the infected animal and comprise growing the budding yeast cell in a media comprising phosphate buffered saline (PBS), 5 g/L of urea and 0.1% dextrose or in a media comprising 150 mM NaCl, 3 mM glucose, and 4 mM urea at a temperature of greater than 37° C. and a pH of about 7.35 with normoxic oxygen levels.
58. The method of claim 54 , wherein the budding yeast cell is a Cryptococcus spp., Candida spp., or Mucor spp.
59. A method of identifying differentially expressed genes in budding yeast cells in response to a test compound, comprising:
(a) growing the budding yeast cell in vitro under infection mimetic conditions to produce a metabolically synchronous population of budding yeast cells;
(b) adding a test compound to the metabolically synchronous population of budding yeast cells;
(c) sampling continuous cultures of the metabolically synchronous population of budding yeast cells of (b) over time; and
(d) identifying one or more genes that are differentially expressed when the budding yeast cells are grown under infection mimetic conditions and in the presence of the test compound as compared to when grown under standard laboratory conditions and in the presence of a test compound.
60. The method of claim 59 wherein the infection mimetic conditions mimic blood of the infected animal and comprise growing the budding yeast cell in a growth media comprising 150 mM NaCl, 5.5 mM glucose, free amino acids, macrophages, neutrophils, and human serum factors at a temperature of greater than 37° C. and a pH of <7.35 with normoxic oxygen levels.
61. The method of claim 59 , wherein the infection mimetic conditions mimic a wound infection in the animal and comprise growing the budding yeast cell in a media comprising less than 150 mM NaCl, 5.5 mM glucose, free amino acids, collagen, elastin, fibronectin macrophages, neutrophils, interleukin, and tumor necrosis factor at a temperature of greater than 37° C. and a pH ranging from 7.15 to 8.9 with hypoxic oxygen levels.
62. The method of claim 59 , wherein the infection mimetic conditions mimic cerebral spinal fluid of the infected animal and comprise growing the budding yeast cell in a media comprising phosphate buffered saline (PBS), 5 g/L of urea and 0.1% dextrose or in a media comprising 150 mM NaCl, 3 mM glucose, and 4 mM urea at a temperature of greater than 37° C. and a pH of about 7.35 with normoxic oxygen levels.
63. The method of claim 59 , wherein the budding yeast cell is a Cryptococcus spp., Candida spp., or Mucor spp.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/360,695 US20210348206A1 (en) | 2015-05-11 | 2021-06-28 | Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562179545P | 2015-05-11 | 2015-05-11 | |
PCT/US2016/031712 WO2016183119A1 (en) | 2015-05-11 | 2016-05-11 | Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom |
US201715572899A | 2017-11-09 | 2017-11-09 | |
US17/360,695 US20210348206A1 (en) | 2015-05-11 | 2021-06-28 | Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/031712 Division WO2016183119A1 (en) | 2015-05-11 | 2016-05-11 | Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom |
US15/572,899 Division US11078515B2 (en) | 2015-05-11 | 2016-05-11 | Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210348206A1 true US20210348206A1 (en) | 2021-11-11 |
Family
ID=57248531
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/572,899 Active US11078515B2 (en) | 2015-05-11 | 2016-05-11 | Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom |
US17/360,695 Pending US20210348206A1 (en) | 2015-05-11 | 2021-06-28 | Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/572,899 Active US11078515B2 (en) | 2015-05-11 | 2016-05-11 | Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom |
Country Status (3)
Country | Link |
---|---|
US (2) | US11078515B2 (en) |
EP (1) | EP3294886A4 (en) |
WO (1) | WO2016183119A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110619925B (en) * | 2019-09-27 | 2022-09-23 | 大连理工大学 | Method for directly predicting biological effectiveness of organic pollutants |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858367A (en) * | 1997-03-27 | 1999-01-12 | Case Western Reserve University | Methods for screening for antimicrobials utilizing AarC and compositions thereof |
US20030108872A1 (en) | 2000-08-23 | 2003-06-12 | Mark Sulavik | Genomics-assisted rapid identification of targets |
WO2002046465A2 (en) | 2000-12-08 | 2002-06-13 | Oxford Biomedica (Uk) Limited | Method for identification of genes involved in specific diseases |
WO2002081734A1 (en) | 2001-04-06 | 2002-10-17 | Department Of Veterans Affairs | Methods for modeling infectious disease and chemosensitivity in cultured cells and tissues |
EP1570738A1 (en) * | 2004-02-12 | 2005-09-07 | Bayer CropScience S.A. | Fungicidal composition comprising a pyridylethylbenzamide derivative and a compound capable of inhibiting the spores germination or mycelium growth by acting on different metabolic routes |
-
2016
- 2016-05-11 EP EP16793387.8A patent/EP3294886A4/en not_active Withdrawn
- 2016-05-11 US US15/572,899 patent/US11078515B2/en active Active
- 2016-05-11 WO PCT/US2016/031712 patent/WO2016183119A1/en active Application Filing
-
2021
- 2021-06-28 US US17/360,695 patent/US20210348206A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3294886A4 (en) | 2019-02-20 |
WO2016183119A1 (en) | 2016-11-17 |
US11078515B2 (en) | 2021-08-03 |
EP3294886A1 (en) | 2018-03-21 |
US20180119136A1 (en) | 2018-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rossi et al. | “It’sa gut feeling”–Escherichia coli biofilm formation in the gastrointestinal tract environment | |
Vila et al. | Targeting Candida albicans filamentation for antifungal drug development | |
Alkawash et al. | Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms | |
Thomann et al. | Application of dual inhibition concept within looped autoregulatory systems toward antivirulence agents against Pseudomonas aeruginosa infections | |
Åmellem et al. | Cell inactivation and cell cycle inhibition as induced by extreme hypoxia: the possible role of cell cycle arrest as a protection against hypoxia‐induced lethal damage | |
Korolev et al. | Turning ecology and evolution against cancer | |
Traverse et al. | Tangled bank of experimentally evolved Burkholderia biofilms reflects selection during chronic infections | |
Kiss et al. | Loss of the oxygen sensor PHD3 enhances the innate immune response to abdominal sepsis | |
Wang et al. | Knockout of Mkp-1 enhances the host inflammatory responses to gram-positive bacteria | |
Shokri | Evaluation of inhibitory effects of citric and tartaric acids and their combination on the growth of Trichophyton mentagrophytes, Aspergillus fumigatus, Candida albicans, and Malassezia furfur | |
Khan et al. | Two small RNAs conserved in Enterobacteriaceae provide intrinsic resistance to antibiotics targeting the cell wall biosynthesis enzyme glucosamine-6-phosphate synthase | |
US20210348206A1 (en) | Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom | |
Hu et al. | Identification, characterization and immunological analysis of Ras related C3 botulinum toxin substrate 1 (Rac1) from grass carp Ctenopharyngodon idella | |
George et al. | Interactions of Salmonella enterica serovar Typhimurium and Pectobacterium carotovorum within a tomato soft rot | |
Gao et al. | The Crohn Disease-associated ATG16L1T300A polymorphism regulates inflammatory responses by modulating TLR-and NLR-mediated signaling | |
White et al. | The role of host molecules in communication with the resident and pathogenic microbiota: a review | |
van't Veer et al. | Delineation of the role of Toll-like receptor signaling during peritonitis by a gradually growing pathogenic Escherichia coli | |
Baldissera et al. | Citrobacter freundii impairs the phosphoryl transfer network in the gills of Rhamdia quelen: Impairment of bioenergetics homeostasis | |
Wang et al. | The nitric oxide synthase gene negatively regulates biofilm formation in Staphylococcus epidermidis | |
Piña et al. | Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors | |
Hoces et al. | Fitness advantage of Bacteroides thetaiotaomicron capsular polysaccharide is dependent on the resident microbiota | |
Wallart et al. | The Biofilm Resistance: Many Responses but Still Many Questions | |
Hower et al. | LPS modifications and AvrA activity of Salmonella enterica serovar Typhimurium are required to prevent Perforin-2 expression by infected fibroblasts and intestinal epithelial cells | |
Secor et al. | The depletion mechanism can actuate bacterial aggregation by self-produced exopolysaccharides and determine species distribution and composition in bacterial aggregates | |
Heinisch | Baker's yeast as a tool for the development of antifungal drugs which target cell integrity–an update |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |